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One feature of cancer is chromosomal instability (CIN). Through moderate CIN, 
most cancer types acquire somatic copy number alterations during each cell di-
vision creating intra-tumor heterogeneity that enhances the overall ‘fitness’ of the 
cancer cell population. Yet, excessive CIN can lead to non-viable karyotypes. 
While CIN-induction in cancer types that are intrinsically genomically instable 
may have little therapeutic benefit, it may cause massive cell death in cancers 
with ‘silent’ or nearly diploid genomes, as for instance in many pediatric cancer 
types including Ewing sarcoma (EwS). 
 
To identify a candidate gene that could offer a large therapeutic window, the re-
sults presented in this thesis focused on protein regulator of cytokinesis 1 (PRC1), 
the most significantly overexpressed cytokinesis-related gene in EwS. PRC1 
plays pivotal roles in orchestrating cytokinesis through its direct involvement in 
bundling of antiparallel microtubules (MTs) required for spindle midzone for-
mation, recruitment of and interaction with other spindle midzone effectors and 
regulatory proteins. 
 
The results presented in this thesis show that EWSR1-FLI1 directly hijacks PRC1, 
which physiologically safeguards controlled cell division, through binding to a 
proximal enhancer-like GGAA-microsatellite (mSat) thereby promoting tumor 
growth and poor clinical outcome. Moreover, high PRC1 expression creates a 
therapeutic vulnerability toward pharmacological PLK1 inhibition at clinically 
achievable dosages that can repress growth of even chemo-resistant EwS cells 
by triggering mitotic catastrophe. 
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1.1 Chromosome instability (CIN) 
1.1.1 Sources of CIN in cancer 
CIN refers to the accumulated gain/loss of chromosomes over cell divisions, 
which is a general feature of cancer [1]. Most human tumors represent chromo-
somal abnormalities indicative of CIN, with a ratio of 60% to 80% [1]. Genetic 
heterogeneity derived from CIN set up a foundation for clonal evolution and se-
lection. It is also positively associated with a higher tumor grade, higher recur-
rence/metastasis, and a reduced patient survival [2]. Furthermore, a large set of 
cancer-related pathways involve CIN. The dysregulation of such pathways can 
change normal chromosome division in mitosis [3]. Indeed, many factors, e.g., 
oncogenic signaling, pre-mitotic replication stress, all promote the development 
of CIN [4]. 
A profound influence of CIN in malignant cells is that it alters mitotic phenotype 
features [5]. For example, cells with lagging chromosomes in the anaphase spin-
dle are the consequences of their defective MT attachments at the kinetochores 
(Figure 1). Other chromosome mis-segregations in mitosis include chromatin/ul-
trafine DNA bridges and acentric fragments. With the exception of aneuploidy 
and severer structural chromosomal alterations, chromosome mis-segregation 
can trigger focal but profound rearrangement known as chromothripsis, double-




Figure 1 CIN in Cancer 
(Figure adopted from Bakhoum and Cantley, Cell, 2018 [6]) 
 
1.1.2 CIN to Cancer: good or bad? 
While being considered as a hall marker of cancer, the involvement of CIN in 
tumor evolution shows both sides of the coin [7]. Aneuploidies induced by CIN 
positively correlate with antineoplastic agents resistance in (pre)clinical settings 
[1]. In contrast, severe CIN can increase sensitivity of tumor cells towards cyto-
toxic and/or radiation treatments [8]. These findings indicate that optimal fitness 
for cancer cell survival is obtained by adjusting CIN into an appropriate scope [8].  
CIN-induced chromosome copy number diversity is a substrate for natural selec-
tion increasing cancer cell viability and promoting immune evasion, enhancing 
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drug response as well as metastasis [9]. Parallelly, chromosome segregation fail-
ures convey a set of cellular stresses (e.g., loss of chromosomes, activation of 
DNA damage signaling as well as proteotoxic stress) (Figure 2) [10]–[12]. 
 
Figure 2 The multi-faceted roles of CIN in cancers  
(Figure adopted from Bakhoum and Cantley, Cell, 2018 [6]). 
 
1.1.3 Induction of high CIN as an anti-tumor therapeutic intervention 
Several studies have reported that multiple mouse models with low CIN rate de-
veloped late onset of low penetrance tumors. However, increasing CIN rate in the 
same study led to cell death and suppressed tumors in multiple settings [13], [14]. 
A similar finding has been verified in vitro as well [15]. Collectively, despite the 
low CIN’s weakly tumor promoting effect, high rates of CIN can inhibit tumor 
growth via inducing massive cell death. Moreover, tumor cells have to limit chro-
mosome mis-segregation rates within a restricted scope maximizing viability in 
order to keep balance between genome instability and the acquisition of hetero-
geneity [8].  
It is conceivable that leveraging CIN rate over a critical threshold could be ex-
ploited therapeutically. As many cancers intrinsically harbor CIN, they are sup-
posed to be more vulnerable than normal dividing cells to CIN-induced agents. In 
this regard, such agents are expected to safeguard proliferating tissues lacking 
CIN [16]. For example, Taxol, PARP inhibitors, as well as ionizing radiation are 
some of the strongest agents inducing chromosome mis-segregation [6].  
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However, despite recent progresses in the knowledge of CIN in the biological 
field, clinical adoptions of CIN-induced interventions are still in their infancy. Alt-
hough demonstration of the CIN has been well demonstrated in cancer cell lines 
or in mouse models, it is still unclear whether such models can faithfully explain 
the types of CIN found in real patients. Moreover, detailed elucidation of genetic 
and epigenetic contributors and outcomes of CIN in human cancers should be 
clearly interpreted. Given the wide spread of CIN in human cancers, CIN-induced 
treatments do have the ability to significantly reshape clinical outcomes, through 
i.e. minimizing the initiation of therapeutic resistance, priming advanced or meta-
static disease. However, careful patient selection is required for determining 
when such intervention will be beneficial to tune CIN and when it might be noto-
rious [17]. 
1.2 Ewing sarcoma (EwS) 
1.2.1 Cell of origin 
EwS is thought to be derived from a single cellular lineage with varying develop-
mental timing of oncogenic conversion followed by damaged differentiation po-
tential because of its lack of genetic subtypes [18]. About 80% of EwS cells are 
present in bone, suggesting progenitors might locate in the developing bone mes-
enchyme [18]. A mesenchymal origin of EwS has also been proposed. It has been 
reported that in EWSR1-FLI1 proficient cells the gene expression pattern mimics 
the ones from neural-crest-derived stem cells, while downregulation of EWSR1-
FLI1 steers the EwS transcriptome towards that of bone-marrow-derived mesen-
chymal stem cells (MSCs) [19]. Additionally, the idea of an epithelial origin has 
been raised as well [20]. 
 
1.2.2 Genetic features 
EwS is a quite gnomically ‘silent’ disease featured by a recurrent balanced chro-
mosomal translocation [21]. The fusion of the FET family gene EWSR1 with the 
ETS family gene FLI1 at t(11;22)(q12;q24) is the most common one (~85%) [22] 
(Figure 3). Through functionally interacting with EWSR1-FLI1, moderate risk al-
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leles might contribute to disease progression [23]. Based on the location of break-
points within EWSR1 and FLI1 genes, various subtypes of EWSR1-FLI1 tran-
scripts have been discovered [24] (Figure 3). Different fusions between EWSR1 
and other members of the ETS family have been identified with ERG (encoding 
transcriptional regulator ERG) being the most commonly one [25]. Subsequently, 
ETV1 [26], ETV4 [27] or FEV [28] fusions to EWSR1 were found. Additionally, 
some variant fusions were identified between ETS genes and EWSR1 paralog of 
the FET gene family (FUS and TAF15) [29] (Figure 3).  
Of note, unlike most developmental malignances, other mutations in EwS are 
unusual. For instance, TP53 and STAG2 mutations are represented at diagnosis 
in 5-7% and 15-21%, respectively [30]. Recurrent chromosomal abnormalities in 
EwS generally involve whole or segmental chromosomes [31], [32]. 
 
Figure 3 Genetic predisposition to EwS.  
(Figure adopted from Grünewald and Cidre-Aranaz, Nature Rev Disease Primers, 2018 [33]) 
Enhancers are dynamically cell-type-specific elements that regulate activation of 
gene expression in a time and space dependent manner. In EwS, the genome-
wide enhancer signature is quite similar [34], which is functionally related to the 
oncogenic transformation by EWSR1-FLI1. GGAA-mSats are EwS specific en-
hancers, acting as pioneer transcription factors surmounting the non-opened 
chromatin state of the GGAA-mSats in EwS [35]–[37]. This interaction increases 
approachability of DNA to other transcription factors, chromatin adjustors and re-
modeling compounds [35], [37]. Notably, it has been reported that EWSR1-FLI1 
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is able to interact with subunits of the BRG1-BRM-assocated factor (BAF) chro-
matin-remodeling compounds, leading to translocation of BAF compound at 
GGAA-mSats [37]. Subsequently, the recruitment triggers chromatin remodeling, 
builds up de novo enhancer elements and activates the EwS transcriptional pro-
gram [37] (Figure 4).  
 
Figure 4 EWSR1-FLi1-mediated epigenetic remodeling of regulatory elements.  
(Figure adopted from Grünewald and Cidre-Aranaz, Nature Rev Disease Primers, 2018 [33]) 
Non-coding RNAs conduct epigenetic regulation in EwS cells as well. Indeed, 
EWSR1-FLI1 regulates a number of non-coding RNAs (e.g. miR-34a, miR-145), 
which actively participate in EwS tumorigenesis [38]. 
 
1.2.3 Pathology, diagnosis and therapy 
Histologically, EwS is classified as a small round cell with round nuclei, a hetero-
geneous group of malignancies that are nevertheless morphologically quite sim-
ilar [39]. Sufficient materials of EwS through a biopsy is required for the precise 
diagnosis for classical histology, immunohistochemistry (IHC), molecular pathol-
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ogy and biobanking [40]. CD99, a cell-surface glycoprotein, is a sufficient auxil-
iary diagnostic indicator for EwS [42]. IHC revealed that ~95% of EwS represent 
high and disperse expression of CD99 in the membrane [39]. However, CD99 
expression is not unique for EwS as it is also broadly expressed in normal tissues 
as well as in other tumors [39]. Recently, our lab found that BCL11B and GLG1 
may serve as specific auxiliary IHC markers in conjunction with CD99 for EwS 
diagnosis when confirmatory molecular diagnosis has failed [42]. Fluorescence-
in-situ-hybridization (FISH)-based detection of EWSR1 rearrangements and/or 
reverse transcription PCR (RT-PCR) as well as detection of FET-ETS gene fu-
sions that are characteristic for EwS have been widely used currently as more 
robust diagnostic tools [43]. Next-generation sequencing (NGS) is recommended 
when FISH and/or RT-PCR cannot produce precise results [33].  
Newly diagnosed EwS patients generally receive a combination of multi-agent 
cytotoxic chemotherapy with local treatment (surgery and/or radiotherapy). 
Chemotherapy is carried out before local treatment in order to minimize the load 
of the local tumor and manage micro-metastatic disease [44]. Metastatic EwS 
patients are treated with agents utilized in localized patients or tested in random-
ized clinical trials aimed at improving patients survival [45]. Recurrent EwS is al-
ways correlated with a very poor survival, with a 5-year survival of less than 10% 
[46]. A highly resistant clone of cancer cells that developed under treatment, may 
explain a potential source of relapse [47]. Admittedly, development of novel treat-
ments for EwS is still at slow pace because of the rarity of EwS. Although several 
clinical trials with EwS patients have been performed, just modest efficacies were 
observed. Thus, it is urgent to search for innovative targeted therapeutic agents, 
e.g., small-molecular inhibitors like YK-4-279 [48]. 
 
1.3 Protein regulator of cytokinesis 1 (PRC1) 
1.3.1 Cytokinesis 
Cytokinesis, the final stage of cell mitosis, physically splits one parental cell to 
two equal offspring. Cytokinesis should be properly done to maintain genome 
stability, the defect of which can lead to aneuploidy contributing to cancer devel-
opment [49]. Accurate time-and-spatial control of cytokinesis ascertains that each 
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offspring gains one complete equal amount of chromosomes, evenly distributed 
cytoplasm and cellular organelles. Such fine-tuned processes are regulated del-
icately by a complex network of fibrillary structures (Figure 5) [50]. 
 
Figure 5 Illustrations the steps in cytokinesis by animals.  
(Figure adopted from Pollard and O’Shaughnessy, Annual Reviews, 2019 [51]) 
1.3.2 Structure and Role of PRC1  
PRC1 contains 620 amino acids. It has multiple domains, namely central micro-
tubule (MT)-binding, rod, dimerization, and Lys/Arg-rich domains (Figure 6a). 
The 5’-terminus comprises alpha-helices featured by a number of coiled-coli (CC) 
motifs. The 3’-terminus consists of beta sheets and turns [52]–[54].  PRC1 coop-
erates with other actin-binding proteins via the interaction of PRC1 central MT-
binding domain with actin-binding protein spectrin domain [55], in which the cen-
tral MT-binding domain is linked to the rod domain through its constituting three 
helices [56]. The structural stability of PRC1 is preserved via the formation of its 
rod domain linked to the dimerization domain [57]. Though the clear functional 
role of Lys/Arg-rich unstructured 3’ terminus is not clear yet, the Lys/Arg-rich un-
structured 3’ terminus is actively involved in increasing the affinity of the central 
MT-binding domain [55], [56]. Additionally, two nuclear localization signals and 
two cyclin-dependent protein kinases (CDK) 1 phosphorylation sites at Thr-470 
and Thr-481 are all located in the 3’-terminus [56]. 
PRC1 is structurally flexible but stable via the formation of various rigid confor-
mations by body rotations. One major function of PRC1 is bundling overlapping 
interpolar MTs (iMTs), which relies on PRC1-formed-homodimers via forming a 
U-shaped hairpin in the dimerization domain. Then, the orientation of two rod 
domains is changed to opposite directions, which is critical for MT crosslinking 
and serves as a platform of recruiting other proteins, e.g., Kinesin family member 




1.3.3 Regulation of PRC1 expression 
Several kinases and phosphatases are tightly regulated and participate in the 
PRC1-involved cytokinesis process. In the early stage of mitosis, CDK1/cyclin B 
phosphorylates PRC1 at Thr-470 and Thr-481  to suppress PRC1 dimerization 
[58]. This process is promoted by TOPK (T-LAK cell-originated protein kinase) 
via forming the CDK1/cyclin B/PRC1 complex [59]. Monomeric PRC1 lacks the 
ability of bundling MT’s and its interaction with KIF4A, though it can bind spindle 
MTs [54], [60] (Figure 6c). 
When entering anaphase from metaphase, the dephosphorylated PRC1 is acti-
vated by the mitotic phosphatases, such as Cdc14A, which enforces PRC1 inter-
action with KIF4A [54]. PRC1 further moves and resides in the plus-ends, where 
PRC1 bundles antiparallel iMTs with the help of KIF4A and then forms midzone 
for other critical microtubule associated proteins (MAPs) [61].  
Moreover, the PP2A regulatory subunit B55a (PP2A-B55a) regulates PRC1 as 
well (Figure 6c). The CDK1-mediated inactivated dephosphorylation of PRC1 
and PP2A-B55a/ENSA/Greatwall pathway-mediated activated dephosphoryla-
tion of PRC1 take place in such a fine-tuned time-and-spatial way that PRC1 is 
completely activated in the early stage of anaphase [62]. 
PRC1 is phosphorylated and bound to polo-like kinase 1 (PLK1) during the ana-
phase (Figure 6d). Polo-kinase binding domain (PBD) is required for such tar-
geting[63], [64], [64], [64]–[67]. Of note, PLK1 shares overlapped CDK1-depend-
ent docking sites for phosphorylation and thus establishes a frame where PLK1 
translocation and activity are finely adjusted in the early stage of mitosis when 
CDK1 is active [68]. Specifically, PRC1 is phosphorylates by CDK1 at Thr-470 
and Thr-481, which avoids PRC1 phosphorylation by PLK1 [68]. Since the func-
tion of CDK1 is inactivated in the early stage of mitosis, PRC1 is phosphorylated 
by PLK1 at Thr-578 and Thr-602 in anaphase, which enhance the affinity of 
PLK1-PRC1 complex. These two different docking sites of PLK1 have different 
roles: PRC1 is activated via phosphorylation at Thr-602. Thr-578 can stabilize 
PBD binding to increase approachability of PRC1 to Thr-602 [68]. Notably, CDK1 
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seemingly has no pre-anaphase regulatory effect on PRC1. Instead, the phos-
phorylation of PRC1 by PLK1 at Thr-602 can ascertain mature midzone assembly 
[69]. 
 
Figure 6 PRC1 modular structure and its expression regulated by several pathways   
(Figure adopted from Li et al. Trends in Cancer, 2018 [70]). 
 
1.3.4 PRC1 is essential for normal cell cytokinesis 
PRC1 is a key player in the network of fibrillary structures required for normal 
cytokinesis. The heterogeneous expression of PRC1 determines the frequency 
of mitosis in different tissue and organs [71]. PRC1 locates in nuclei in interphase 
and then moves to the spindle when entering into mitosis. Finally, PRC1 resides 
in midzone post-mitotic bridges until the end of cytokinesis [52].  
PRC1 plays essential roles in spindle midzone formation.  PRC1 crosslinks iMTs 
to maintain the stability of two iMTs [60]. This process has been further facilitated 
by the central MT-binding domain of PRC1 [55]. The 3’-terminus of PRC1 ascer-
tains fine-tuned flexible linking between two antiparallel MT filaments, which en-
hances PRC1 crossing-linking activity [55]. The resulting cross-bridge determines 
the distance between interdigitating MTs (35 nm), which influences the interac-
tions of PRC1 with other motor proteins [55], [72]. Silencing of PRC1 strongly 
disables iMTs bounding activity and disrupts spindle midzone formation, subse-
quently causing significant mitotic defects [58], [73].  
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Cleavage furrow ingression (CFI) relies on synergistic work of contractile ring with 
spindle midzone. PRC1 directly interacts with kinesin family member 14 (KIF14) 
to promote citron kinase translocation to the midzone, thereby providing mainte-
nance of the spindle stability over the period of constriction to abscission [74]–
[76]. 
K-fibers provide mechanical pulling forces, with which interkinetochore stress be-
tween sister kinetochores is adjusted by bridging fibers. In order to preserve the 
curve-shaped spindle in the metaphase, bridging fibers where PRC1 stretches 
from spindle midzone to the position of kinetochores link k fibers internally [77]. 
These findings suggest that PRC1-enriched fibers can bind to sister k fiber. 
 
1.3.5 PRC1 in tumorigenesis 
Silencing of PRC1 induces generations of binucleated cells, the accumulation of 
which is a major risk factor of aneuploidy formation [58]. PRC1 overexpression 
also causes abnormal ploidy formation, potentially owing to obstruction of the 
well-adjusted cytokinesis. Remarkably, PRC1 ranked as the second highest CIN-
associated gene in a large gene set comprising 10,151 genes from different can-
cer entities [78]. PRC1 overexpression was related with strong abnormal ploidy 
formation followed by a poor overall survival in a CIN signature [78]. Tetraploid, 
a common consequence generated by cytokinesis defects, promotes severe an-
euploidy, tumor progression and worse survival of patients  [79]–[81]. Indeed, 
while physiologically PRC1 seems to safeguard genome stability [81], PRC1 is 
commonly dysregulated in different cancers, suggesting the prognostic value of 
PRC1 in cancer. 
Therapeutically targeting PRC1’s upstream kinases and/or pathways may pro-
vide novel approaches to disrupt delicate cytokinesis/mitosis that induce CIN in 
cancer. Despite the expression/activity of PRC1 can be adjusted by some indirect 
approaches in cancer, identifying drugs which directly target PRC1 is urgently 
required. By the same token, more studies are required towards achieving a 
clearer and more comprehensive understanding of the manner in which PRC1 
promotes tumorigenesis and CIN. 
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2. Research Design 
2.1 Objectives 
EwS is a bone and soft-tissue cancer with highly aggressive behaviors. It mostly 
affects children, adolescents, and young adults. EwS often shows an unfavorable 
clinical course, despite very intensive therapies. Especially patient’s prognostic 
value is still unsatisfied, which urges the development of innovative and in partic-
ular less toxic therapeutic options for EwS patients. 
Genetically, EwS is characterized by pathognomonic EWSR1-ETS fusion onco-
genes (in 85% EWSR1-FLI1), which encodes aberrant transcription factors that 
massively rewire the tumor transcriptome. Despite rapid proliferation, EwS cells 
maintain a remarkably stable genome. In fact, most EwS do not show any other 
genomic abnormality than EWSR1-ETS and exhibit a largely diploid genome 
without CIN, which is maintained by a fine-tuned balance of mitosis and cell divi-
sion (cytokinesis). 
This PhD project aimed at targeting the delicate balance between mitosis and 
cytokinesis that could drive EwS cells into cell death, which may constitute a new 
approach for targeted therapy. 
 
2.2 Scientific aims 
1st aim: Analysis of the PRC1 expression pattern in EwS, other pediatric cancers, 
and normal tissues as well as prospective validation of PRC1 as a prognostic 
marker. 
2nd aim: Investigation of EWSR1-FLI1 mediated PRC1 expression in EwS. 
3rd aim: Functional characterization of the phenotypic effects of PRC1 in vitro and 
in vivo. 
4th aim: Evaluation and validation of the transcriptomic effects of PRC1 silencing. 
5th aim: Analysis of CIN and aneuploidy induced by PRC1 silencing and/or PLK1 
inhibition in vitro and in vivo. 
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6th aim: Functional characterization of PRC1-dependent effects of PLK1 inhibition 
in vitro and in vivo 
7th aim: Functional characterization of PRC1-dependent effects of PLK1 inhibition 
in combination with chemo-reagents in vitro. 
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3. Materials and methods 
3.1 Materials 
3.1.1 List of manufacturers 
Manufacturer Location 
(Carl) Roth Karlsruhe, Germany 
Abcam Cambridge, UK 
Agilent Technologies Santa Clara, USA 
Applied Biosystems Darmstadt, Germany 
ATCC Rockville, Maryland, USA 
BD Biosciences Europe Heidelberg, Germany 
Biochrom Berlin, Germany 
BioRad Richmond, California, USA 
Cambio Cambridge, UK 
Cell Marque Corporation Rocklin, California, USA 
Cell Signaling Technology Frankfurt a. M., Germany 
Corning incorporated New York, USA 
Eppendorf Hamburg, Germany 
Falcon Oxnard, California, USA 
Fischer Scientific Schwerte, Germany 
Gilson Incorporated Middleton, USA 
HP Labortechnik München, Germany 
IDT technologies Coralville, Iowa, USA  
INTEGRA biosciences Zizers, Switzerland 
Invitrogen Karlsruhe, Germany 
InVivoGen San Diego, California, USA 
Leica Biosystems Wetzlar, Germany 
LI-COR Nebraska, USA 
Life Technologies California, USA 
Macherey-Nagel  Düren, Germany 
Merck Millipore Burlington, Massachusetts, 
USA New England BioLabs Frankfurt a. M., Germany 
OriGene Technologies Rockville, Maryland, USA 
Pechiney Plastic Packaging Menasha, Wisconsin, USA 
Promega Madison, Wisconsin, USA 
Proteintech Group Leon-Rot, Germany 
Qiagen Chatsworth, California, USA 
OriGene Technologies Rockville, USA 
Roche Mannheim, Germany 
Santa Cruz Biotechnology  Heidelberg, Germany 
Selleckchem Munich, Germany 
Sigma-Aldridge St. Louis, Missouri, USA 
Takara Bio Europe Saint-Germain-end-Laye, 
France Thermo Fisher Scientific  Ulm, Germany 
Thermo Scientific Braunschweig, Germany 
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Zeiss Oberkochen, Germany 
 
3.1.2 General materials 
Material Manufacturer 
6, 12, 24 and 96-well-plate Corning Incorporated 
96-well-plate (white) Corning Incorporated 
Amersham Protran 0.45 nitrocellulose Western blotting 
membranes 
GE Healthcare 
Blotting paper Hartenstein 
Cell culture flasks (150, 75, 25 cm) Corning Incorporated 
Cell scraper Corning Incorporated 
Costar Ultralow attachment plates 96-well Corning Incorporated 
Eppendorf Tubes (1.5 and 2 ml) Hartenstein 
Falcon Tubes (15 ml and 50 ml PP or PS) Falcon 
HandyStep electronic Brand 
Heating lamp Beurer GmbH 
Nunclon cell culture dish (10 cm) Thermofisher 
Optical adhesive film for 96er PCR-Plates Fisher Scientific 
Parafilm  Pechiney Plastic Packaging 
Pasteur Pipette  Hartenstein 
PCR-Plates (96-well) Fisher Scientific 
Pipetboy INTEGRA Biosciences 
Pipette tips (10 µl, 20 µl, 100 µl, 200 µl, 1000 µl) Biozym 
Pipettes (0.5-10 µl, 10-100 µl, 100-1000 µl) Gilson  
Scalpels  Mergo GmbH & Ko KG 
Stripette (2, 5, 10, 25 and 50 ml) Corning Incorporated 
Needle and syringe for intravenous injection (BD Micro-
Fine™+ Insulin)  
BD Biosciences 
Syringes for viruses (0,45 μm) (Carl) Roth 
 
3.1.3 Mice strains 
Mouse strain Manufacturer 
NSG (NOD.CG-SCID): 
NOD-scid IL2Rgammanull, NOD-scid IL2Rgnull, 
NSG, NOD scid gamma 
 
The Jackson Laboratory 
NOD/SCID: 
NOD/MrkBomTac-Prkdcscid Taconia Denmark ApS 
 
3.1.4 Instruments and equipments 
Device Specification Manufacturer 
Affymetrix-Gene Chip Human Clariom™ D Thermofisher 
Autoclave Varioklav HP Laboratortechnik 
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Bacteria incubator Kelvitron Heraeus 
Bacteria shaker Certomat IS Braun BioTech internat. 
Cell counter Countess II Thermofisher 
Centrifuge Heraeus™ Megafuge ™ 40 Heraeus 
Centrifuge Centrifuge (5424 R and 5430) Eppendorf 
Controlled-freezing box Mr. Frosty Nalgene 
Electrophoresis Mini Trans-Blot Biorad 
ELISA reader Varioskan ™ LUX Thermofisher 
Flow Cytometer BD Accuri™ C6 BD Biosciences 
Freezer (-20°C) No Frost Siemens 
Freezer (-80°C) B 35-50 Fryka 
Gel documentation Multi Image Light Cabinet Alpha Innotech 
Hemocytometer C-Chip Biochrom 
Ice maker SPR80 Nordcap 
Incubator Heracell™ 240i CO incubator Thermofisher 




Microscope (TMA) Axioplan 2 imaging Zeiss 
Multichannel pipette  Transferpette-12 electronic Brand  
Nanodrop Nanodrop ND-1000 UV/Vis Thermofisher 
pH-meter pH-197  WtW 
Power Supply  PowerPac ™ Biorad 
RT-qPCR software  Bio-Rad CFX Connect™ Biorad 
Scale GE1302 Sartorius 
SDS-PAGE chamber Mini Trans-Blot  Biorad 
Shaker Unimax 1010 DT Heidolph Instruments  
Sterile bench Maxisafe2020  Thermofisher 
Thermocycler  T100 TM Thermal Cycler  Biorad 
Thermomixer  Thermomixer comfort  Eppendorf 
Vortex Vortex-Genie 2 Scientific Industries 
Waterbath ED-5 Julabo  
Western blot documen-
tation 




Acrylamide/Bisacrylamid (Carl) Roth 
Agar Sigma-Aldrich 
Agarose Sigma-Aldrich 
Ammonium Persulfate (APS) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
BI2536 Selleck 
BI6727 (Volasertib) Selleck 
Bovine albumin (BSA) Sigma-Aldrich 
Dimethylsulfoxid (DMSO) Sigma-Aldrich 
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Dithiothreitol (DTT) Sigma-Aldrich 
Doxycycline Hyclate (HPLC) Sigma-Aldrich 
Ethanol (99%) (Carl) Roth 
Glacial acetic acid Sigma-Aldrich 
Glycine (Carl) Roth 
Isopropanol (Carl) Roth 
L-glutamine Sigma-Aldrich 
LB-Medium (Carl) Roth 
Methanol (100%) (Carl) Roth 
Milk powder (Carl) Roth 
N-acetylcysteine (Nac) Sigma-Aldrich 
Resazurin Sigma-Aldrich 
Sodium Chloride (NaCl)  (Carl) Roth 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sodium Orthovanadate (Na3VO4) Sigma-Aldrich 





0.1N HCI endotoxin free Sigma-Aldrich 
 
3.1.6 Biological reagents 
Reagents Manufacturer 
1-kbp DNA-ladder (Carl) Roth 
100-bp DNA-ladder (Carl) Roth 
4% Formalin Sigma-Aldrich 
Accutase Sigma-Aldrich 
AEC+ Substrate-Chromogen Agilent Technologies 
AgeI-HF New England BioLabs 
Beetle- and Renilla-Juice PJK 
Bovine serum albumin Sigma-Aldrich 
Bradford reagent Biorad 
Crystal violet Sigma-Aldrich 
Deoxynucleotide triphosphates (dNTPs) Sigma-Aldrich 
Dh5α competent cells Thermofisher 
DMEM with 3.7 g/l NaHCO3, with 1.0 g/l D-glu-
cose 
Biochrom 
EcoRI-HF New England BioLabs 
Fetal bovine serum (Tetracycline-free) Sigma-Aldrich 
G418 InVivoGen 
GeneRuler 100 bp Plus DNA Ladder Life Technologies 
GoTaq G2 Hot Start Polymerase Promega 
Hematoxylin Vector Laboratories 
HEPES Sigma-Aldrich 
Hexadimethrinbromide (polybrene) Sigma-Aldrich 
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HindIII-HF New England BioLabs 
Hypotonic solution (75 mM KCl) Merck 
Immobilon Western HRP Substrate Merck 
iTaq™ Universal Probe Supermix (2X) Bio-Rad 
Lipofectamine LTX Reagent with PLUS Reagent Invitrogen 
Lipofectamine LTX with Plus Reagent Thermofisher 
Lipofectamine RNAiMax  Invitrogen  
Maxima Hot Start Taq DNA Polymerase  Thermo Scientific 
Maxima Hot Start Taq Polymerase  Thermo scientific 
Opti-MEM Medium Life Technologies 
PageRuler Prestained Protein Ladder Thermofisher 
Penicillin-Streptomycin-Glutamine (100x) Life Technologies 
Penicillin/Streptomycin Biochrom 
Phosphate Buffered Saline (PBS) Biochrom 
Phusion High-Fidelity DNA Polymerase  Thermo Scientific 
Plasmocure  InVivoGen 
Propidium-iodide  Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
Puromycin InVivoGen 
Quick Start Bovine Serum Albumin Standard Biorad 
RNase  Thermofisher 
RPMI 1640 with 2.0 g/l NaHCO3 500 ml Biochrom 
Stellar competent cells Takara 
Streptavidin HRP Leica Biosystems 
Sucrose > 99.5% (GC) Sigma-Aldrich 
SYBRSELECT Master Mix Life Technologies 
T4 DNA Ligase (HC) Promega 
T4 Ligase Thermo Scientific 
Target Retrieval Solution Agilent Technologies 
Trypan blue Sigma-Aldrich 
Trypsin/EDTA (10x) Biochrom 
XhoI Thermo Scientific 
 
3.1.7 Commercial kits 
Kit Manufacturer Reference 
FITC Amplification Kit (2 Step) Cambio 1084-KF-50 
FITC Annexin V Apoptosis Detection kit I BD Biosciences 556547 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814 
ImmPRESS H R P Anti-Mouse IgG Polymer De-
tection Kit 
Vector Laboratories MP-7402 
ImmPRESS H R P anti-rabbit IgG Polymer Detection 
Kit 
Vector Laboratories MP-7401 
NucleoSpin Gel and PCR      Clean-up Macherey-Nagel 740609 
NucleoSpin RNA Macherey-Nagel 740955 
NucleoSpin Tissue/DNA Macherey-Nagel 740952 
PureYield Plasmid Midiprep System Promega A2495 
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QIAGEN Plasmid Maxi Kit Qiagen 12162 




3.1.8 Restriction enzymes 
Name Sequence (5’→3’) Manufacturer Reference 
AgeI-HF (20U) ACCGGT New England BioLabs R3552S 
EcoRI-HF (20U) GATATC New England BioLabs R3195S 
HindIII-HF (20U) AAGCTT New England BioLabs R3104S 
KpnI-HF (20U) GGTAC New England BioLabs R3142S 
XhoI-HF (20U) CTCGAG New England BioLabs R0146S 
 
3.1.9 Primary and secondary antibodies for Western blot and 
immunohistochemistry 
Antibody Manufacturer Reference 
anti-CD99 Abcam Ab8855 
anti-human mitochondria antibody Abcam Ab92842 
anti-mouse IgG ImmPress MP-7402 
anti-phospho-gH2AX Abcam Ab81299 
anti-rabbit IgG ImmPress MP-7401 
Goat polyclonal anti-mouse IgG(H+L)-HRP Promega W402B 
Goat polyclonal anti-rabbit IgG-HRP OriGene EU R1364HRP 
Mouse monoclonal anti-GAPDH Santa Cruz Sc-32233 
Rabbit monoclonal anti-Ki67 Cell marque 275R-15 
Rabbit polyclonal anti-Cleaved Caspase 3 Cell Signaling 9661 
Rabbit polyclonal anti-PRC1 Proteintech 15617-1-AP 
Rabbit polyclonal anti-PRC1 Proteintech 15617-1-AP 
 
3.1.10 Buffer and solutions 
Solution Composition 
1 M Tris-HCl; pH = 6.8 30.3g Tris up to 250 ml H 2O 
1.5 M Tris-HCl; pH = 8.8 45.4g Tris up to 250 ml H 2O 
1× Blotting buffer 100 ml 10 × R/B buffer; 700 ml H2O; 200 ml methanol 
1× Running buffer 100 ml 10 × R/B buffer; 900 ml H2O; 10 ml 10% SDS 
1× TBS 100 ml 10 × TBS; 900 ml H2O 
1× TBST 100 ml 10 × TBS; 900 ml H2O; 1 ml Tween-20 
10% APS 1g ammonium persulfate; 10 ml H2O 
10% SDS 10g SDS; 100 ml H2O 
10× RIPA Buffer 150 mM NaCl; 1% triton X-100; 0.5% sodium deoxy-cholate; 0.1% SDS; 50 mM Tris-HCl, pH = 8 
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10× Running/Blotting 
buffer (10× R/B buffer) 
(pH = 8.3) 
30g Tris-Base; 144g glycine 
10× TAE electrophoresis 
buffer 
48.4g Tris-Base, 11.4 ml glacial acetic acid, 3.7g EDTA, 
fill up to 1L with H2O 
10× TBS (pH = 7.3) 24g Tris-Base; 88g NaCl 
4× Loading dye 250 mM DTT to 1 ml loading dye 
Blocking buffer  5% non-fat dried milk or 5% BSA in 1x TBST 
DMEM glutaMax medium 500 ml DMEM medium, 10% FCS, 1% P/S 
Electrophoresis gel 100 ml 1× TAE buffer, X% agarose, 4 µl EtBr 
Freezing solution 10% DMSO, 45% FCS and 45% normal medium 
RPMI medium 500 ml RPMI 1640 medium, 10% FCS, 1% Penicil-
lin/Streptomycin (P/S) 
 
3.1.11 SDS-PAGE gel compositions 
Resolving gel (7.5 ml) 10% 
H2O 2.9 ml 
1.5 M Tris-HCl (pH = 8.8) 2ml 
30% (w/v) Acrylamide/Bisacrylamid 2.5 ml 
10% (w/v) SDS 75 µl 
10% (w/v) APS 40 µl 
TEMED 10 µl 
 
Stacking gel (5ml) 3% 
H2O 3.5 ml 
1 M Tris-HCl (pH = 6.8) 860 µl 
30% (w/v) Acrylamide/Bisacrylamid 500 µl 
10% (w/v) SDS 48 µl 
10% (w/v) APS 40 µl 
TEMED 10 µl 
 
3.1.12  Oligos Sequences 
 shRNA sequence for pLKO-Tet-On cloning 









































 PRC1_RV CAACCGATCCACTTCTAATTG 
 pGL3_PRC1_mSat_FW CGGGGTACCGGGTCTCGCTTTCTTG 
 pGL3_PRC1_mSat_RV CTAGCTAGCAGTTGCCACTTCATCCTA 
 EWSR1-FLI1_FW GCCAAGCTCCAAGTCAATATAGC 
 EWSR1_FLI1_RV GAGGCCAGAATTCATGTTATTGC 
 Tet-pLKO_FW GGCAGGGATATTCACCATTAT 
Tet-pLKO_RV CTATTCTTTCCCCTGCACTG 
 
 CRISPR gRNA/crRNA sequences 
















 3C-sequence primer/probe 
Name of Oligo Sequence (5’ → 3’) 
PRC1-mSat-Taqman-probe FAM-CCCAGCCATGTCTAATCTAATGAGCCC-
TAMRA 
 PRC1-mSat-constant-fragment-RV CACTGTAAGAGAAATGAAGAAAGCC 
Test-fragment I (PRC1-promoter) GTTTCCCTCGCTCATCCAA 
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Test-fragment II AGGGATACAGAGCAGGTTCTA 
 
Test-fragment III TGTCACAGACATTATGAGCTGAA 
 
Test-fragment IV CCCTCAGGGTGTATAGTGTAGA 
GAPDH loading control-FW CTGTCTGCTTCTCTGCTGTAG 
GAPDH loading control-RV TTCACACCCATGACGAACAT 
ERCC3 ligation control Taq-
Man-probe 
FAM-TTTACCCAGCAAGCCAGCAAGTCT-TAMRA 
ERCC3 ligation control-FW TCTTATGAAGGCTGGGAGGA 













HindIII-test-II cut-FW AGGGATACAGAGCAGGTTCTA 
HindIII-test-II cut-RV GTATTGTGGAATTGTGCGAAGAG 
HindIII-test-II uncut-FW GTGAGGCCCTGTCTCAAATAA 
HindIII-test-II uncut-RV TTCCCTAGAGTCCTGTCCTTAG 
HindIII-test-III cut-FW TGTCACAGACATTATGAGCTGAA 
HindIII-test-III cut-RV GCTGCTCAAAGGAGGAAAGA 
HindIII-test-III uncut-FW TGGTCAGCCAATCGTTTCTAC 
HindIII-test-III uncut-RV TGACCTCTCTTTCTTGCCATTT 
HindIII-test-IV cut-FW CCCTCAGGGTGTATAGTGTAGA 
HindIII-test-IV cut-RV TTTATGTGTGTGTGTATGTGTGTG 
HindIII-test-IV uncut-FW GCCTCTCAGGCTCAAGTAATC 
HindIII-test-IV uncut-RV GCGAGACCCTGTCTCTACTAA 
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 Primers for sequencing 
 







Vector name Number Manufacturer 
pCAG-YFP # 11180 Addgene 
pCEF-VSV-G (env) # 41792 Addgene 
pCMV-GFP # 11153 Addgene 
pGL3-Promoter Vector # E1761 Promega 
pHAGE TRE dCas9-KRAB #50917 Addgene 
pLKO.1-puro U6 sgRNA BfuAI large 
stuffer # 52628 Addgene 
psPAX2 # 12259 Addgene 




BD Accuri C6 Software BD Biosciences 
Bio Rad CFX Manager 3.1 Biorad 
Cytoscape 3.8.1 Cytoscape 
GraphPad PRISM 8 GraphPad 
Image J www.rsbweb.nih.gov/ij/ 
Image Studio Lite LI-COR 
Photoshop 2020 Adobe 
R-project https://www.r-project.org/ 
 SnapGene GSL Biotech 
SPSS  IBM  
 




 pGL3-promoter vector establishment 
To evaluate whether EWSR1-FLI1 interacts with a distal enhancer-like GGAA-
mSat about 90kb telemetric away from PRC1 promoter, 1,053 bp fragment in-
cluding PRC1-associated GGAA-mSats (hg19 coordinates: chr15:91,623,953-
91,625,005) from three EwS cell lines (A673, TC71 and EW-1)  were inserted into 
the pGL3-Fluc vector (Promega, #E1761). The backbone vector was linearized 
via double digestion (KpnI and NheI) at 37°C for 3 hrs (Table 1). A673, TC71 and 
EW-1 genome DNA (gDNA) were extracted according to NucleoSpin Tissue kit  
manual instruction and adjusted to a final concentration of 100 ng/µl. 
Name Volume (µl) 
pGL3-Promoter vector (1µg) Variant 
10× CutSmart buffer 10 
KpnI 1 
NheI 1 
dH2O Up to 50 µl 
Table 1 pGL3-Promoter vector linearization 
Primers were specifically designed by Primer Premier and BLAT in UCSC 
(https://genome.ucsc.edu/cgi-bin/hgBlat) to check specificity in hg genome. An 
In-Silico PCR has been performed via UCSC In-Silico PCR tool (https://ge-
nome.ucsc.edu/cgibin/hgPcr?hgsid=879734033_fYCe8o5jbApFjbAp-
FxKk8yA87GWs), which yields desired PCR amplicon without any non-specific 
amplification. The target mSat-amplicon was amplified from pre-diluted gDNA 
(100 ng) by using corresponding primer pair with overhangs. PCR amplification 
program was set up in Table 2. 
Name Volume (µl) 
Phusion HF buffer (5X) 10 
pGL3_PRC1_mSat-FW (10 µM) 2.5 
pGL3_PRC1_mSat-RV (10 µM) 2.5 
Phusion HF polymerase 0.5 
gDNA (100 ng/µl) 1 
dNTP (10 mM) 1 
DMSO 1.5 
dH2O = up to 50 
Table 2 Recipe of mSat amplification from gDNA 
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A touch-down (TD) PCR was used in order to avoid non-specific amplification 
(Table 3). The annealing temperature (Ta) of mSat primer pair was calculated via 
NEB Tm calculator online tool (https://tmcalculator.neb.com/#!/main). The start 
annealing temperature of TD-PCR was 5°C higher than the actual Ta value, with 
a gradient cooling process (-0.5°C/cycle) for 10 cycles. The last 25 cycles of PCR 
amplification were annealed at the actual Ta value. Elongation time was deter-
mined according to the length of the desired amplicon. 
Step °C Time Cycles 
Initialization 98 30 sec 1 







Elongation 72 30 sec 




Annealing 50 30 sec 
Extension 72 30 sec 
Final Extension 72 10 min  
Table 3 PCR amplification program for Phusion-mediated mSat-PCR- amplification 
The right band was cut and extracted with the NucleoSpin PCR and Gel clean up 
kit. Extra variants devoid of the GGAA-mSat was excluded by whole genome 
sequencing (WGS) of the parental cell lines and Sanger sequencing of the cloned 
fragments. Sequenced mSat fragment was ligated to digested pGL3-promoter 
vector (50 ng) with T4 ligase (NEB) in a molar insert : vector ratios of 5:1. The 
required mass of insert for the indicated ratio was calculated via NEB ligate cal-
culator (http://nebiocalculator.neb.com/#!/ligation) (Figure 7). 
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Figure 7 Calculation of the mass of mSat insert 
Calculation of the mass of mSat insert needed for linearized pGL3-promoter vector (http://nebio-
calculator.neb.com/#!/ligation). 
55 ng mSat fragment was ligated to 50 ng linearized pGL3-promoter vector in a 
20 µl ligation system at 16°C overnight (Table 4).  
Components Sample Neg. Ctrl 
Insert x µl mSat-fragment  
(55 ng) 
X µl ddH2O 
Linearized backbone vector 50 ng  50 ng 
Ligation buffer (10X) 2 µl 2 µl 
T4 ligase (400 U/µl) 1 µl 1 µl 
dH2O = up to 20 µl = up to 20 µl 
Table 4 Ligation reactions of mSat fragment with pGL3 backbone 
An extra heating step (65°C, 10 min) was carried out for enzyme inactivation. The 
cloned pGL3-mSat vector is showed in Figure 8. 
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Figure 8 Cloning with the pLKO-Tet-On system 
 
 pLKO-Tet-On system establishment 
In order to establish PRC1 stable knockdown cell lines, the pLKO-Tet-On system for 
inducible shRNA expression was used [82]. The cloning was carried out according 
to Wiederschain ’s protocol [83] [Addgene (Plasmid # 21915)]. 
shRNA sequences with corresponding restriction overhang used in the pLKO-
Tet-On vector were listed in Table 5. “Genetic Perturbation Platform (GPP) Web 
Portal” from the Broad institute was used for sequence designing. A scrambled 
sequence was used for the control (Table 5). 
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Top CCGG CAGGAACATTC AAAGGCATTT CTCGAG 
AAATGCCTTTGAA 
TGTTCCTG TTTTTG 







Top CCGG GCCTGACTTCTC TACCACATA CTCGAG 
TATGTGGTAGAG 
AAGTCAGGC TTTTTG 
 TATGTGGTAGAG AAGTCAGGC CTCGAG 
GCCTGACTTCTC 
TACCACATA CAAAAA AATT bot-
tom 
sh_Control: 
Top CCGG CAACAAGATGAA GAGCACCAA CTCGAG 
TTGGTGCTCTTCA 
TCTTGTTG TTTTTG  
 TTGGTGCTCTTCA TCTTGTTG CTCGAG 
CAACAAGATGAA 
GAGCACCAA CAAAAA AATT bot-
tom 
Table 5 Sequences of shRNAs against PRC1 or control. 
A double digestion was performed by using AgeI and EcoRI restriction enzymes 
in the Tet-pLKO-puro vector (Table 6): 
Name Volume (µl) 
CutSmart buffer (10X) 2 
AgeI 2 
EcoRI 2 
4 µg Tet-pLKO-puro vector variant 
dH2O Up to 20 
Table 6 Linearization of Tet-pLKO-puro vector 
Plasmid digestion was performed following the NEB manual instructions by mix-
ing digestion solutions together to double their final yield. The digested vector 
backbone was collected via sodium acetate/ethanol precipitation and reformu-
lated with dH2O. The vector has been verified by gel (about 8800 bp for linearized 
vector) and was cut for purification. 
Before ligation, shRNA was first annealed. Forward and Reverse oligo were re-
constituted in ddH2O in a final concentration of 100 µM. 11.25 µl of each 100 µM 
Materials and methods 41 
 41 
primers were pooled together and 2.5 µl 10X annealing buffer was added to the mixed 
primer solution in a PCR-tube. An annealing process was described in Table 7.  
Step °C 
Start temperature 95 
Annealing -1°C /min 
End temperature 14°C 
Table 7 Oligo annealing 
Dilute 1 µl of the primer mixture 1:400 in 0.5X annealing buffer. Digested back-
bone vector and annealed shRNA was ligated at 16°C for 16 h (Table 8): 
Name Volume  (µl) 
Gel-purified digested pLKO-
Tet-On (10-20 ng) variant 
Oligo dilution 1 
10X  Ligase buffer 1.5 
T4 DNA ligase 1 
dH2O up to 15 
Table 8 Ligation reaction of cloned Tet-pLKO-puro vector  
The cloned Tet-pLKO-puro vector is noted in Figure 9. 
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Figure 9 Vector map of cloned Tet-pLKO-puro 
 
 Transformation and clone verification 
Transform Stellar Competent cells (50 µl) with 4 µl of the total ligation reaction 
volume in 1.5 ml Eppendorf tube followed the manual instruction 
(https://www.takarabio.com/documents/User%20Manual/PT5055/PT5055-2.pdf). 
Briefly, pre-chill ligation on ice for 30 min, heat shock for exactly 45 sec at 42°C, 
and incubate on ice for 2 min. Add 500 µl pre-warmed SOC-medium to the stellar 
competent cells and incubate at 37°C while shaking for 1.5 h. Plate 100 µl of 
E.coli cells onto pre-warmed LB plates (Amp 100 µg/ml) for an overnight incuba-
tion at 37°C with shaking. 
The colony touch-down (TD) PCR was performed to verify the right clones. Pick 
single colonies and incubate in 100 µl LB-Medium (100 µg/ml ampicillin) for 2 h 
while shaking at 37°C.  
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Name Volume (µl) 
Gotaq green buffer (5X) 10 
dNTPs (10 mM) 1 
MgCl (25 M) 6 
10 µM FW primer 2.5 
10 µM RV primer 2.5 
Gotaq polymerase 0.25 
Colony solution 3 
dH2O           up to 50 
Total volume 50 
Table 9 Components of colony PCR 
 
The colony-PCR mix is shown in Table 9: 







Tet-pLKO_FW: 5’- GGCAGGGATATTCACCATTAT–3’ 
Tet-pLKO_RV: 5’- CTATTCTTTCCCCTGCACTG–3’ 
 
The colony-PCR program has a longer initialization time, as the bacterial mem-
brane should be completely destroyed first to expose the plasmid. The PCR-pro-
gram was set up in Table 10: 
Step °C Time Cycles 
Initialization 95 10 min 1 
Denaturation 98 10 sec 
1- 
10th 
Annealing X* 30 sec 
Elongation 72 1 min 
Denaturation 98 10 sec 11th 
- 30th 
Annealing X** 30 sec 
Extension 72 1 min 
Final Extension 72 ∞   
Table 10 Protocol of colony-PCR program 
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X*: The Ta for first 10 cycles should be adjusted on Tm of primer pairs and the DNA polymerases 
used in PCR-process: For pGL3_mSat vector: Ta = 55-50°C; Tet-pLKO_shPRC1/shCtrl vector: 
Ta = 59-49°C.  
X**: The Ta for the rest 20 cycles is the actual annealing temperature of the primer pairs used: 
For pGL3_mSat: 49°C; For Tet-pLKO_shPRC1/shCtrl vector: 56°C. 
 
Resolve PCR products on 1.5% agarose gel: mSat insert = 1053 bp, 
shPRC1/shCtrl insert: 420 bp. 
Inoculate midiprep cultures in 100 ml LB/Amp medium (100 µg/ml) at 37°C over-
night with constant shaking (350 rpm).  
 
 pGL3-mSat and Tet-pLKO-shPRC1/shCtrl Sanger sequencing 
Sanger sequencing was carried out by using corresponding sequence primers to 
exclude potentially introduced point mutation during transformation with E.coli. 
The primers for sequencing were formulated to 10 µM with dH2O. Plasmid was 
adjusted to 75 ng with dH2O (30 µl). 
 
3.2.2 Cell Culture 
 Cell lines 
Ewing Sarcoma 
A673, RDES, SK-N-MC, TC32, EW1 and TC71. 
The A673/TR/shEF1 was established by Dr. med. Martin Orth. 
Others 
HEK-293 (Human embryonic kidney cell line) 
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Cell line Description 
A673 Established from the primary tumor of a 15-year-old girl [84] 
RDES Established from humerus of a 19-year-old man 
SK-N-MC Established in 1971 of a 14-year-old Caucasian female with an Askin’s tu-
mor 
EW1 Established from the tumor of a 17-year-old man 
TC32 Established from the tumor of a 17 years old female [85] 
TC71 Established from the tumor of a 22-year-old man with metastatic Ewing sar-
coma 
Table 11 Description of EwS cell lines used. 
 
 General cell culture 
RPMI-1640 or DMEM medium including 10% tetracycline-free fetal calf serum 
(FCS) and 100 U/ml Penicillin and 100 µg/ml Streptomycin (P/S) were selectively 
used for normal cell culture depending on cell lines. Cells were growing in humid-
ified incubator at 37°C (5% CO2). About 1 × 106 cells/ml were frozen at -80°C for 
a short-term and in liquid nitrogen for long-term storage by adding 1 ml freezing 
medium (10% Dimethyl Sulfoxide (DMSO), 45% FCS and 45% normal culture 
medium) to the cell pellet.  
When cells were confluent, cells were passaging by washing with PBS 1X and 
trypsinized. Mycoplasma test was performed regularly by nested PCR every 3 
months. Short Tandem Repeat (STR)-profiling was carried out every half year. 
 
 Establishment of Doxorubicin-resistant EwS cells 
Doxorubicin-resistant (Doxo-res) EwS cells (A673 Doxo-res and TC71 Doxo-res) 
were established through continuous culture with serially increasing Doxo con-
centrations starting at ~10 nM corresponding to pre-determined 50% inhibitory 
concentration (IC50) values. After the successfully adaptation to the given con-
centrations indicated by re-growth, cells were cultured with serially ascending 
Doxo concentrations by multiplying the IC50 values by factor 1.1–2.0. Doxo-res 
variants were maintained with ~200 nM Doxo. 
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 Lentivirus transfection and transduction 
5 × 106 HEK-293T cells were seeded in 10 ml DMEM-glutaMAX medium (10% 
FCS and 1% P/S) one day before transfection.12 µg DNA plasmid, 9 µg psPAX2 
and 3 µg VSV-G were mixed to OptiMEM and the transfection was done followed 
the Lipofectamine LTX (Thermo Fisher) manual instruction. Old medium was re-
placed by 10 ml virus harvest medium (DMEM-GlutaMAX + 30% FCS + 15 mM 
HEPES w/o P/S) 6 h after transfection in order to reduce toxicity and accelerate 
virus production. 48 h after transfection, the virus supernatant was gathered by 
spinning down at 500 g for 10 min to get rid of debris. The virus supernatant was 
then filtered via 0.45 µm filter and stored at 4°C temporarily. 5 ml fresh pre-
warmed virus harvest medium was added gently to the flask for the 2nd virus pro-
duction. 2nd virus supernatant was collected and treated as mentioned above and 
mix with the 1st virus supernatant together. The pooled virus supernatants were 
condensed 20X via Lenti-Concentrator and the virus pellets were resuspended 
with cold PBS.   
At the same time 5 × 105 cells/ T25 flask were pre-cultured 24 h before transduc-
tion in normal cell culture medium. 500 µl concentrated virus supernatant was 
added to 2.5 ml DMEM-GlutaMAX complete medium (10% FCS + 1% P/S) con-
taining polybrene (8 µg/ml). Polybrene was removed 8 h after transduction by 
replacing with normal complete medium. The cells were then incubated for 72 h. 
Successfully transduced cells containing antibiotic-resistance cassette were se-
lected by using proper antibiotics.  
 
 CRISPR interference 
The pLKO.1-puro U6 sgRNA BfuAI large stuffer plasmid (#52628) was used for 
expressing sgRNA. The pHAGE TRE dCas9-KRAB lentiviral plasmid (#50917) 
encodes dCas9-KRAB fusion protein. Candidate sgRNAs were designed by 
searching for G(N)20GG motifs 150 bases upstream/downstream of the PRC1-
associated GGAA-mSat. Relevant off-target matches were determined and ruled 
out by CRISPR-Cas9 guide RNA design checker (IDT). SgRNAs were then 
cloned individually in the digested pLKO.1-puro U6 sgRNA BfuAI large stuffer 
plasmid and verified by Sanger-sequencing (Figure 10). Lentivirus was produced 
as described above (see 3.2.2.4). A673 and RDES cells were first transduced 
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with pHAGE TRE dCas9-KRAB plasmid and selected with G418 (800 µg/ml). 
Cells stably expressing dCas9-KRAB protein (Figure 11) were then transduced 
with pLKO.1-sgRNA lentiviral particles and treated with puromycin (1 µg/ml) and 
G418 (400 µg/ml) to select and maintain successfully transduced cells. An 
sgRNA targeting the Green fluorescent protein (GFP) gene was used as the neg-
ative control. 
 
Figure 10 The pLKO.1-puro U6 sgRNA BfuAI large stuffer lentiviral plasmid backbone with 
sgRNA as insert 
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Figure 11 The pHAGE TRE dCas9-KRAB lentiviral plasmid encoding dCas9-KRAB 
 
 CRISPR-Cas9 homology-directed repair editing 
Publicly available gRNA design tool from IDT (https://eu.idtdna.com/site/or-
der/designtool/index/CRISPR_CUSTOM) was used to identify high-scoring can-
didates gRNAs complementary to two target regions flanking the PRC1-associ-
ated GGAA-mSat motifs (Figure 12).  
 
Figure 12 Representative map of CRISPR-Cas9 cutting position in PRC1-associated mSat. 
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Each crRNA (CRISPR RNA) (IDT, Alt-R CRISPR-Cas9 crRNA, custom design) 
was mixed with tracrRNA (trans-activating crRNA) (IDT, Alt-R CRISPR-Cas9 tra-
crRNA) in equimolar concentrations to form crRNA:tracrRNA duplexes (10 µM). 
The crRNA:tracrRNA duplexes were heated at 95°C and gradually cooled down 
to room temperature (RT) (20-25°C). The up- and downstream RNA complexes 
were mixed in equimolar concentrations and then incubated with Cas9 HIFI V3 
nuclease (IDT, Alt-R S.p. HiFi Cas9 Nuclease V3, #369268) for 5 min at room 
temperature to assemble the RNP complex. A negative control (ctrl) ctRNP was 
established at the same time (IDT, Alt-R Cas9 Negative Control). Ultramer 
ssODN donor of either homologous arms alone (50 bp up- and downstream) or 
homologous arm plus a 24-GGAA-insert (196 bp) was added to the RNP complex 
individually and incubated for 5 min at RT to generate the RNP mixture (ssODN 
final concentration 4 µM). The RNP mixture was added to diluted CRISPR MAX 
reagent (Invitrogen) to generate the RNP lipid complex of a final concentration of 
90 nM. The ctRNP transfection solution was then incubated for 13 min at RT. 
EwS cells were synchronized in the G2/M phase via incubation with Nocodazole 
for 16 h (200 ng/ml) followed by a release of 1 h release before transfection. 50 
µl of the ctRNP transfection solution were added to 100 µl synchronized cell sus-
pension (40,000 cells) with HDR enhancer (final concentration 30 µM) (IDT, Alt-
R® HDR Enhancer) seeded in triplicates in 96-well plates. Transfected cells were 
incubated at 37°C (5% CO2) and the medium from cells was replaced by fresh 
medium without HDR enhancer after 24 h. Genomic DNA isolation and detection 
of editing efficacy at bulk level were performed 48 h after transfection by assess-
ment of the fluorescence intensity, and by PCR amplification and gel-electropho-
resis. Finally, single-cell cloning was carried out to select successfully edited 
clones, which were verified by Sanger-sequencing (Figure 13). 
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Figure 13 CRISPR-modified mSat gel image 
Representative images of agarose gel electrophoresis of amplicons containing the wildtype (wt) 
PRC1-associated GGAA-mSat, CRISPR Cas9-edited negative control (NC), or CRISPR Cas9-
initiated HDR edited KO of A673 and RDES cells, as well as the insertion of 24-GGAA repeats in 
A673 cells (100 bp DNA ladder). 
 
3.2.3 Molecular biology 
 Reverse transcription, and quantitative RT-PCR 
High-Capacity cDNA Reverse Transcription Kit was used for cDNA synthesis (Ta-
ble 12): 
Name Volume  (µl) 
RT  buffer (10X) 2 
Random primers (10X) 2 
dNTP Mix (100 mM) 0.8 
Reverse Transcriptase (50 U/µl) 0.8 
RNA diluted with dH2O 14.4 
Table 12 cDNA synthesis components. 
The qRT-PCR reactions were performed using ‘SYBR green master mix’ (Table 
13) with Bio-Rad CFX Connect instrument. Data analysis was carried out by using 
Bio Rad CFX Manager 3.1 software. 
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Name Volume (µl) 
SYBR green master mix (2X)  10 
10 µM FW/RV primer mix 1.0 
Diluted cDNA  9.0 
Table 13 qRT-PCR with SYBR dye 
Gene expression values were calculated using the “2^−(ΔΔCt) method” [86]. 
RPLP0 was used as internal control.  
The qRT-PCR reaction was set up as follows (Table 14): 
Step °C Time Cycles 
Heat activation 95 2 min 1 
Denaturation 95 10 sec 50 
Annealing 60 20 sec 
Extension 60 20 sec 
Final denaturation 95 30 sec 1 
Table 14 qRT-PCR with SYBR dye program 
 DNA extraction and RNA extraction, 
1 × 107 cells were extracted with the NucleoSpin Tissue/DNA or RNA kit accord-
ing to manual instructions. DNA or RNA concentration was measured by 
Nanodrop. 
 
 Chromatin conformation capture (3C) PCR assays 
In order to check if heterogenous expression of PRC1 in EwS can be mediated 
through long-range direct physical interactions of EWSR1-FLI1 between PRC1 
promotor via binding to a distant GGAA-enhancer like mSat, chromosome con-
formation capture (3C) PCR assays were performed to test such looping interac-
tions. 
The 3C PCR-seq was carried out as previously described with minimal modifica-
tions [87]. Briefly, 1×107 cells were fixed with 1% formaldehyde in PBS/10% FCS 
and incubated for 10 min at RT while tumbling. This cross-linking was inactivated 
by glycine (125 mM) and washed with PBS. Fixed cells were lysate in a pre-cold 
lysis solution (10 mM Tris, pH 8.0, 10mM NaCl, 0.2% NP40 and a protease in-
hibitor cocktail [Roche]) under constant shaking for 15 min. The formaldehyde-
crosslinked nuclei were harvested and washed with 1.2X RE buffer and then re-
suspended into 0.5 ml 1.2X RE buffer with addition of sodium dodecyl sulfate 
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(SDS) (0.3%). The mixture was incubated for 20 min at 65°C followed by 40 min 
at 37°C with shaking at 1,200 rpm. The solution containing 2% Triton X-100 was 
further incubated for 1 h at 37°C with shaking at 1,200 rpm. The DNA was first 
digested with 400 U HindIII-HF (NEB) for 6 h at 37°C (1,200 rpm). Another 400 
U HindIII-HF was used for a second digestion at 37°C overnight (1,200 rpm). After 
collection of the digested solution, the solution was diluted in 7 ml 1X ligation 
buffer. Then, the solution/1% Triton X-100 was incubated at 37°C for 1 h while 
gently shaking. Next, DNA was ligated with 100 U T4 DNA Ligase (HC) (Promega) 
for 4 h at 16°C and then for 45 min at RT. Crosslinks were reversed by 300 µg 
proteinase K for an overnight incubation at 65°C. Residual RNAs in the sample 
were digested by RNase A. DNA was purified by phenol-chloroform extraction 
and dissolved in 100 µl of 10 mM Tris (pH 7.5).  
Perform real-time PCR quantifications (SYBR Green) on both samples (undi-
gested and digested) using the qPCR conditions detailed in Table 15,16. Diges-
tion efficiencies were monitored by SYBR qPCR with primer pairs that amplify 
genomic regions containing or devoid of HindIII digestion sites. The digestion ef-
ficiency should be above 60–70%.  
Component Volume Final concentration 
H2O 6 µl  
Forward primer (10 µM) 1 µl (10 pmol) 0.5 µM 
Reverse primer (10 µM) 1 µl (10 pmol) 0.5 µM 
SYBY master mix (2X) 10 µl  
50X dilution of 3C sample 2 µl  








UDG Activation 50°C 2 min Hold 
AmpliTaq® Fast DNA polymerase, UP Acti-
vation 
95°C 2 min Hold 
Denature 95°C 15 sec 40 
Anneal/Extend 60°C 1 min 
Table 16 Thermal cycling conditions using SYBER-dyed for digestion efficacy test. 
TaqMan real-time PCR was carried out for quantification of ligation products (Ta-
ble 17, 18). A random ligation control was generated using a bacterial artificial 
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chromosome (BAC; clone CH17-26I20, CHORI BACPAC Resources Center) har-
boring all ligation products under study. The ligation frequency was calculated as 
a ratio of the 3C ligation product to the corresponding product in the random liga-
tion control by normalization with ERCC3 [87]. 
 
Component Volume Final concentration 
H2O 2 µl  
Test primer (10 µM) 0.5 µl (5 pmol) 0.5 µM 
Constant primer (10 µM) 0.5 µl (5 pmol) 0.5 µM 
iTaq™ Universal Probe Supermix (2X) 5 µl  
TaqMan probe (1.5µM) 1 µl (1.5 pmol) 0.15 µM 
3C sample (200 ng/µl) 1 µl  
Table 17 10 µl qPCRs system for ligation frequency of 3C samples 
 
Step Temperature Duration Cycles 
Polymerase Activation & DNA De-
naturation 
95°C 3 min Hold 
Denaturation 95°C 5 sec 40 
Anneal/Extend + Plate read 60°C 30 sec 
Table 18 10 µl qPCRs system for ligation frequency of 3C samples. 
 
3.2.4 Biochemistry 
 Protein preparation and quantification 
5 × 105 cells were seeded in 6-well plate treated with/without Dox (1µg/ml) for 72 
h to induce PRC1 knockdown. Whole cellular proteins were collected with 100 µl 
RIPA buffer including 1 mM Na3VO4 and 100 µl/ml protease inhibitor cocktail. 
Bradford protein assay was used for protein concentration measurement [88].  
 
 Western blotting 
Proteins were separated on a 10% gel, and blotted on PVDF membranes. Mem-
branes were incubated with rabbit polyclonal anti-PRC1 antibody (1:1,000, 
15617-1-AP, Proteintech) or mouse monoclonal anti-GAPDH (1:800, sc-32233, 
Santa Cruz). Then, membranes were incubated with horseradish peroxidase 
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(HRP) coupled anti-rabbit IgG (H+L) (1:5,000, R1364HRP, OriGene) or anti-
mouse IgG (H+L) (1:3,000, W402B, Promega). Proteins were detected using 
chemiluminescence HRP substrate (Millipore-Merck). 
 
3.2.5 In vitro assays 
 Proliferation assay 
2×105 EwS cells harboring dox-inducible shRNA against PRC1 or CRISPR Cas9-
initiaed HDR-edited EwS cells were seeded in 6-well plates. 1 µg/ml Dox was 
used for inducing PRC1 knockdown for 72 h and refreshed every 48 h. 
A673/TRE/dCas9/sgPRC1 or sgGFP and RDES/TRE/dCas9/sgPRC1 or sgGFP 
cells were treated with/without Dox (2 µg/ml) for 14 d with regular media changes 
(Dox refreshed every 48 h). Cells (including supernatant) was counted within 
standardized hemocytometers (C-Chip, Biochrom) using the Trypan-Blue 
(Sigma-Aldrich) exclusion method. 
 Colony forming assay (2D/3D)  
For 2D Colony forming assay, 300 cells of RDES, SK-N-MC, and TC32 cells har-
boring Dox-inducible shRNAs against PRC1 and respective control/ RDES and 
TC32 EwS cells treated with indicated dose of PLK1 inhibitors (BI2536 or BI6727) 
were seeded and cultured in triplicates in 12-well plates for 12–16 d. Dox (1 µg/ml) 
was used for PRC1 knockdown and refreshed every 48 h. Thereafter, Crystal-
Violet solution (Sigma-Aldrich) was used for colony staining. ImageJ Plugin Col-
ony area was used for colony number/size measurement. The clonogenicity in-
dex was calculated as: colony number X colony area. 
For 3D sphere formation assay, 500 cells of RDES, SK-N-MC, and TC32 cells 
harboring Dox-inducible shRNAs against PRC1 and respective control/ RDES 
and TC32 EwS cells treated with indicated dose of PLK1 inhibitors (BI2536 or 
BI6727) / CRISPR Cas9-initiated HDR edited A673 cells were in 96-well Costar 
Ultra-low attachment plates (Corning) in 100 µl standard cell culture for 14 d. For 
shRNA-mediated EwS cells, 10 µl of fresh medium with/without Dox was applied 
to each well every 48 h. PLK1 inhibitor at indicated doses were applied to RDES 
and TC32 cells when seeding without any refreshment afterwards. On day 14, 
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wells were photographed, and sphere numbers and diameters were analyzed by 
means of ImageJ using the formula A=π×d2/4. 
 
 Propidium iodide staining 
8×105 RDES, SK-N-MC, and TC32 cells harboring a Dox-inducible shRNA 
against PRC1 and respective control cells were seeded in 10 cm dish with/without 
addition of Dox (1 µg/ml) for 72 h. Dox was renewed 48 h after seeding. Ice-cold 
70% ethanol was taken for cell fixation. 100 µg/ml RNAse (ThermoFisher) was 
added to the fixed cell solution, which was then stained with 50 µg/ml propidium 
iodide (PI) (Sigma Aldrich). At least 1 X 105 events were gated and analyzed with 
BD Accuri C6 Cytometer (Figure 14). 
 
Figure 14 Representative gating steps for PI cell cycle analysis. 
 
 Annexin V staining 
8×105 RDES, SK-N-MC, and TC32 cells harboring a Dox-inducible shRNA 
against PRC1 and respective control cells were seeded in 10 cm dish with/without 
addition of Dox (1 µg/ml) for 72 h. Dox was renewed 48 h after seeding. 8×105 
RDES and TC32 EwS cells treated with indicated dose of PLK1 inhibitors (BI2536 
or BI6727) were seeded in 10 cm dish for 72 h. Cells were washed with PBS 1X 
and the pellet was collected by centrifuging at 1200 rpm, 4min. Cell pellet was 
resuspended by 500 µl 1x Annexin V buffer (5 µl of Annexin V + 5 µl PI solution) 
and incubated at RT for 15 min in the dark. At least 1 X 105 events was gated and 
analyzed with BD Accuri C6 Cytometer within 1h (Figure 15). 
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Figure 15 Representative gating steps for Annexin V cell apoptosis analysis. 
 
 Drug-response assay 
For PLK1 inhibitor treatment, 5,000 cells/well of Dox-inducible shRNA expressing 
RDES and TC32 EwS cells were seeded in triplicate wells of 96-well plates. Cells 
were pre-treated for 48 h with Dox to induce the PRC1 knockdown before addition 
of BI2536 (S1109, Selleckchem) or BI6727 (Volasertib; S2235, Selleckchem). 
Cells were then treated with 0–1,000 nM BI2536 or BI6727 (Volasertib) with/with-
out Dox for additional 72 h. The same assays were carried out with wt and 
CRISPR Cas9-initiaed HDR edited A673 cell with a pre-incubation time of only 
24 h to permit surface adherence. At the experimental endpoint, cell growth inhi-
bition was assessed using a Resazurin assay (Sigma-Aldrich) based on manual 
instruction. PRISM 8 (GraphPad Software Inc., CA, USA) was used for calculat-
ing IC50 values. 
 Drug combination analysis 
For drug combination assays, 5,000 cells of Dox-inducible shRNA expressing 
RDES and TC32 EwS cells were seeded in triplicate wells of 96-well plates. Cells 
were pre-treated for 48 h with Dox to induce the PRC1 knockdown. Then, cells 
were treated with 0–100 nM PLK1 inhibitor, 0–4 nM Vincristine (VCR) and/or 0–
100 nM Doxorubicin (Doxo). Inhibition of cell growth was assessed 72 h after start 
of the treatment using a Resazurin assay. Excess over Bliss was calculated using 
synergyfinder (R package v.2.2.4) [89]. For assessment of the dose reduction 
index (DRI), 5,000 cells/well of RDES and TC32 EwS cells were seeded in tripli-
cate wells of 96-well plates 24 h before addition of PLK1 inhibitors. Cells were 
treated with 0–100 nM PLK1 inhibitor, 0–4 nM VCR alone or in combination in a 
1:1 constant combination ratio as previously described [90]. Inhibition of cell 
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growth was assessed 72 h after start of the treatment using a Resazurin assay. 
CompuSyn (ComboSyn, Inc.) was used for determining the DRI of each PLK1 
inhibitor at the IC50 level. 
 
 Doxo-resistance reversal assays 
For Doxo-resistance reversal assays, non-toxic concentrations (<IC10) of PLK1 
inhibitors BI2536 or BI6727 in two Doxo-res EwS cell lines (A673 Doxo-res; TC71 
Doxo-res) was determined by a Resazurin assay after PLK1 inhibition (0–1,000 
nM) for 72 h, respectively. In Doxo-resistant cell lines, the differential in vitro effi-
cacy of Doxo depending on the co-treatment with PLK1 inhibitor BI2536 or 
BI6727, was assessed by a Resazurin assay. To this end, cells were treated for 
72 h with different concentrations of Doxo (0–2,000 nM) and co-treated with the 
non-toxic dosage of PLK1 inhibitor BI2536 or BI6727 (10 nM) as defined above. 
The predicted ED50 concentrations were calculated using CompuSyn (Com-
boSyn, Inc.). For both cell lines, the reverse index (RI) was calculated by dividing 
the ED50 of Doxo alone by the ED50 of the combination-treatment (Doxo plus 10 
nM of PLK1 inhibitor). 
 
 Fluorescence-in-situ-hybridization (FISH) 
After shRNA-induced PRC1 knockdown or PLK1 inhibitor treatment for 48 h, EwS 
cells with ~70% confluency were incubated for 6 h with 0.2 mg/ml colcemid 
(D1925 Sigma 10 µg/ml in HBSS). Cells were collected and incubated in a pre-
warmed hypotonic solution (75 mM KCl) for 30 min at 37°C, and fixed in fresh, 
ice-cold Carnoy’s fixative for 3×15 min. The fixed cells were kept overnight at 4°C. 
20 µl of fixed sample was dropped onto pre-cold clean slides and allowed to air 
dry overnight. For chromosome counts, the cells were incubated with pan-cen-
tromere probe coupled with fluorescein isothiocyanate (FITC) dye (Star*FISH, 
1695-F-02, Cambio, UK) following the manufacturer’s instructions with modifica-
tions. Slides were kept in dark at 4°C. Analysis was carried out using a fluores-
cence microscope (Zeiss AxioVision MC 50, 100W HBO lamp) with a triple dye 
filter (DAPI, propidium iodide and FITC). Images were captured using AxioVision 
4.9 software, and when necessary, signals were enhanced for optimal contrast 
using Adobe Photoshop 2020. Approximately 200 nuclei were evaluated in each 
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set from at least 3 independent experiments (at least 35 nuclei). The karyotypic 
changes were classified and quantified according to the International Standard of 
Cytogenetic Nomenclature (ISCN) [91]: aneuploidy (chromosome loss/gain), 
non-congressed, multipolar, and ‘monster’ cells. 
 
 Luciferase assay 
2×105 A673/TR/shEF1 cells were co-transfected with the pGL3-promotor vectors 
with inserted mSat and Renilla pGL3-Rluc vectors (Promega) (ratio 100:1) in a 6-
well plate by using the Lipofectamine LTX transfection kit (Thermo Fisher)  ac-
cording to its manual instruction. Transfection medium was replaced by medium 
with/without Doxycycline (Dox) (1 μg/ml; Sigma-Aldrich) 4 h after transfection. 
After 72 h the cells were lysed. The transcription activity has been measured by 
a dual luciferase assay system (Berthold). Firefly luciferase activity was normal-
ized to Renilla luciferase activity. 
 
3.2.6 Histology 
 IHC staining. 
The slides received the antigen retrieval treatment and were stained with either 
polyclonal anti-PRC1 antibody (1:200, 15617-1-AP, Proteintech), polyclonal anti-
CC3 primary antibody (1:100; 9661, Cell Signaling), monoclonal anti-phospho-
γH2AX (1:8,000, ab81299, Abcam), monoclonal anti-human mitochondria anti-
body (1:1,000; ab92824, Abcam) or with monoclonal anti-Ki-67 (1:200, 275R-15, 
Cell Marque) for 60 min at RT. A monoclonal secondary horseradish peroxidase 
(HRP)-coupled horse-anti-rabbit antibody (ImmPRESS Reagent Kit, MP-
7401/MP-7402, Vector Laboratories) was carried out depending on antibody spe-
cies afterwards. AEC-Plus (K3461, Agilent Technologies) was used as chromo-
gen. Samples were counterstained with hematoxylin (H-3401, Vector Laborato-
ries). DAB+ (K3468, Agilent Technologies) was used as chromogen and hema-
toxylin for counterstaining. For CD99 staining, slides were stained with monoclo-
nal anti-human CD99 antibody raised in mouse (1:40, ab8855, Abcam) for 32 min 
using the ultraView detection kit in a VENTANA BenchMark system (Roche, Ba-
sel, Switzerland), and counterstained with hematoxylin. 
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 IHC quantification 
To assess tissue integrity and for detection of mitotic defects, e.g., ,monster’ cells, 
FFPE blocks of EwS xenografts were stained with hematoxylin and eosin (H&E). 
Evaluation was performed similar to scoring of hormone receptor Immune Reac-
tive Score (IRS) as previously described [92] (Table 19). The final IRS was de-
termined by multiplying these two grades. Evaluation of Ki-67, CC3, and phos-
pho-γH2AX immunoreactivity were quantified based on their positive staining per-
centage of cells per high-power field (HPF). Examination of 5–15 HPFs of at least 
one section is required for each sample. 
% of expression Grade Intensity classification Grade 
0-19 0 None 0 
20-39 1 Low 1 
40-59 2 Moderate 2 
60-79 3 Strong 3 
80-100 4   
Table 19 IRS score of IHC quantification 
 
 Human samples and ethics approval 
Human FFPE tissue samples were retrieved from the archives of the Institute of 
Pathology of the LMU Munich (Germany) and the Gerhard-Domagk Institute of 
Pathology of the University of Münster (Germany) with approval of the institutional 
review boards. All patients gave informed consent. Tissue-microarrays (TMAs) 
were stained and analyzed with approval of the ethics committee of the LMU Mu-
nich (approval no. 550-16 UE). 
 
3.2.7 Survival analysis 
A public-available cohort comprising tumor samples of 196 primary EwS tumors 
with clinical annotations were analyzed [93]. PRC1 transcription expression was 
stratified as low (1st Third), moderate (2nd Third) and high (3rd Third). The expres-
sion of PRC1 was analyzed in a cohort of 144 EwS patients with available clinical 
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annotation by IHC staining. PRC1 expression was stratified by different IRS val-
ues in those with low (IRS<2), moderate (IRS:2-5) and high (IRS>5). P value in 
overall survival (OS) analysis was assessed by the Kaplan-Meier method (Log- 
rank Mantel-Cox test). 
 
3.2.8 In vivo models 
 Xenograft subcutaneously injected with shRNA-mediated cells 
5×106 EwS cells were injected subcutaneously in a 1:1 mix of cells suspended in 
HBSS formulated with Calcium and Magnesium (ThermoFisher) of 10–12 weeks 
old NOD/Scid/gamma (NSG) mice. Tumor diameters were measured every two 
day. Tumor volume was calculated by the formula (L×l2)/2. When the tumors 
reached an average volume of ~100 mm3, mice were randomized in different 
groups according to the purpose of each experiment. For mice injected with Dox-
inducible shRNA against PRC1 EwS cells, 2 mg/ml BelaDox (Bela-pharm) dis-
solved in drinking water containing 5% sucrose (Sigma-Aldrich) was used to in-
duce an in vivo knockdown. Mice injected with control cells only received 5% 
sucrose (control). All mice were sacrificed by cervical dislocation once tumor vol-
ume of the last mouse in control group exceeded 1,500 mm3. Then, xenograft 
tumors were extracted and fixed in 4%-formalin and paraffin-embedded (FFPE) 
for (immuno)histology. 
 
 Intravenous injection of PLK1 inhibitors 
5×106 CRISPR Cas9-initiated HDR edited PRC1-associated mSat KO A673 cells 
and CRISPR Cas9-edited negative control (NC) cells were subcutaneously in-
jected in mice of 10-12-week-old. When tumors were growing to an average vol-
ume of ~100 mm3, mice were randomized and treated once per week intrave-
nously (i.v.) with 40 mg/kg BI2536, 30 mg/kg BI6727 (Volasertib) or vehicle (0.1N 
HCI with 0.9% saline) for 3–4 weeks. Mice were sacrificed by cervical dislocation 
once the tumor volume of the last mouse in the control group exceeded 1,500 
mm3 or after the last cycle of treatment. Then, xenograft tumors were extracted 
and fixed in 4%-formalin and paraffin-embedded (FFPE) for (immuno)histology. 
Animal experiments were approved by the government of Upper Bavaria and 
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conducted in accordance with ARRIVE guidelines, recommendations of the Eu-
ropean Community (86/609/EEC), and UKCCCR (guidelines for the welfare and 
use of animals in cancer research). 
 
3.2.9 In silico analysis 
 Chromatin immuno-precipitation DNA sequencing (ChIP-Seq) 
ENCODE SK-N-MC DNase-Seq (GSM736570) and ChIP-Seq data (GSE61944) 
were extracted from the GEO, analyzed as previously described and loaded in 











 Enriched GO analysis 
To identify genes involved in cytokinesis in EwS, we used curated publicly avail-
able gene expression data generated on Affymetrix HG-U133 Plus2.0 DNA mi-
croarrays for 979 samples comprising 50 EwS tumor samples and 929 normal 
tissue samples (71 normal tissue types) [94]. First, differential gene expression 
and statistical significance levels were calculated with limma (R package, 
v,3.44.3) [95]. Then, the resulting P-values were adjusted for multiple testing 
based on false discovery rate (FDR) correction. Finally, only differentially ex-
pressed genes with significant fold changes (FCs) (FDR-adjusted P<0.05) were 
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analyzed for Gene Ontology (GO)-term enrichment using clusterProfiler (R pack-
age, v,3.16.1) [96]. Annotation of GO-terms was done using the org.Hs.eg.db (R 
package, v,3.11.4). 
 
 Transcriptome analysis 
Extracted RNAs from EwS cells with/without PRC1 silencing for 60 h were tran-
scriptome profiled at IMGM laboratories (Martinsried, Germany). Samples with 
RNA integrity numbers (RIN) > 9 were hybridized to Human Affymetrix Clariom D 
microarrays. SST-RMA algorithm was used for data normalization via Transcrip-
tome Analysis Console (v4.0; Thermo Fisher Scientific). Annotation was per-
formed using the Affymetrix library for Clariom D Array (version 2, human) on 
gene level. Differentially expressed genes (DEGs) with consistent and significant 
FCs across shRNAs and cell lines were identified in our previously published pa-
per [97] as shown in Figure 16:  
 
Figure 16 Identification of DEGs and establishment of pre-rank gene list 
fgsea (R package, v,1.14.0) was used for pre-ranked gene-set enrichment anal-
ysis (GSEA) annotated by GO definitions from MSigDB (v7.0, c2.cgp.all) [98], 
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[99]. Filtered GO terms (adjusted P<0.01; |Normalized enrichment score|>1.75) 
(Appendix A) were used to create a symmetric GO adjacency matrix based on 
the Jaccard distance between GO terms and respective gene lists. GO clusters 
were identified using dynamicTreeCut (R package, v.1.63.1), and the GO network 
was visualized in Cytoscape (v.3.8.0) [100]. 
 
3.2.10  Statistics 
If not otherwise specified in the figure legends, data are presented as box-dot-
plots with horizontal bars representing means and whiskers indicating the stand-
ard error of the mean (SEM). Data analysis was carried out by using PRISM 8 
(GraphPad Software Inc., CA, USA) or R project. Comparison of two groups in 
functional in vitro and in vivo experiments was calculated by using a two-sided 
Mann-Whitney test. Contingency tables of FISH counting were carried out by the 
Chi-square or Fisher’s exact test as appropriate. Pearson correlation analysis 
was done and visualized using the R package ggpubr (v,0.4.0). Statistical differ-
ences between the groups were assessed by a Mantel-Haenszel test. Cox multi-
variate statistical analyses were carried out in IBM SPSS Statistics software (ver-
sion 23.0; IBM Corp). P-values <0.05 were classified as statistically significant 





CIN is a hallmark of cancer [101]. Yet, many childhood cancers, such as EwS, 
feature remarkably ‘silent’ genomes with minimal CIN [102]. PRC1 plays key roles 
in assembling a complete  functional spindle midzone [58], [103]. Its role involved 
in microtubule-bundling activity assures proper spindle midzone formation [104]. 
Thus, this thesis aims to investigate by means of the EwS model how uncoupling 
of mitosis and cytokinesis via targeting PRC1 or its activating PLK1 can be em-
ployed to induce fatal genomic instability and tumor regression. 
 
4.1 PRC1 is the most highly overexpressed cytokinesis-related gene in 
EwS and correlates with poor overall survival in EwS patients. 
4.1.1 PRC1 is the most highly overexpressed cytokinesis-related gene in 
EwS 
Curated expression data of 929 normal tissue samples (71 tissue types) and 50 
primary EwS tumors were analyzed to search for significantly overexpressed 
genes in EwS compared to normal tissues [105] (Figure 17). Among its versatile 
and profound role in normal cell division and cellular structure formation (Figure 
18), PRC1 exhibited the greatest fold change among 77 significantly overex-
pressed cytokinesis-related genes (FDR-adjusted P<0.05) (Figure 19), being on 
average ~8-fold higher expressed in EwS than in normal tissues (Figure 20). 
These results indicated that PRC1 could be a proper candidate offering a large 




Figure 17 Volcano plot of DEGs 
Volcano plot showing differentially expressed genes (DEGs) in EwS (50 samples) compared to 
normal tissues (929 samples). P value less than 5% FDR adjustment was used as the threshold. 
 
 
Figure 18 GO enrichment analysis  






Figure 19 PRC1 is the most overexpressed cytokinesis-related gene in EwS 
Displayed are 77 significantly upregulated genes in EwS compared to normal tissues (linear fold 
change (FC)>1, FDR P<0.05) that are annotated for the GO-term cytokinesis (GO:0000910). 
MKI67 encoding the proliferation marker Ki-67 was used as a comparator. PRC1 and its direct 
interacting/binding partners, such as cytokinesis defect 4 (CYK4), aurora kinase B (AURKB), the 
kinesin family members 14 and 4A (KIF14/4A) as well as PLK1, have been indicated by arrows. 
 
 
Figure 20 PRC1 overexpressed in EwS in comparison to normal tissues 
Analysis of PRC1 mRNA expression in 50 EwS and 929 normal tissues (comprising 71 normal 
tissue types). Horizontal bars indicate median expression levels, boxes the interquartile range, 





4.1.2 The prognostic value of PRC1 in EwS patients 
An established patient cohort (n=196) in which EwS tumors were profiled on gene 
expression microarray was analyzed [94]. A Kaplan-Meier analysis revealed that 
high PRC1 expression is associated with poor OS of EwS patients (P=0.005) 
(Figure 21). To verify this result at the protein level, a tissue-microarray (TMA) 
comprising 144 independent EwS samples with a specific anti-PRC1-antibody 
(specificity proven through in vivo knockdown experiments) was stained by IHC. 
Although EwS tumors showed on average relatively strong immunoreactivity for 
PRC1, substantial inter-tumor heterogeneity was observed, which allowed semi-
quantitative grouping of tumors based on PRC1 expression. While 54% (78/144) 
of samples did not express detectable levels of PRC1, 24% (35/144) displayed 
low, and 21% (31/144) high expression. Kaplan-Meier analysis confirmed that 
patients with PRC1 overexpression had a poor overall survival as compared to 
patients with low or absent PRC1 expression (P=0.0037) (Figure 22). Further-
more, Cox multivariate analysis indicated that, in addition to the status of metas-
tasis, PRC1 overexpression is an independent prognostic factor in EwS patients 
(OR:3.1, P=0.04) (Table 20). 
 
Figure 21 Kaplan-Meier survival analysis of 196 EwS patients stratified by thirds of PRC1 






Figure 22 Overexpression of PRC1 at protein level correlates with poor overall survival in 
EwS 
Upper: IHC staining of a TMA comprising 144 primary EwS tumors for PRC1. Scale bar=200 µm; 
Lower: Kaplan-Meier analysis of overall survival of 144 EwS patients stratified by their intra-tu-





Factors OR (95% CI) p 
age >20 not included in the variants   
   0.385 
     
gender not included in the variants   
   0.72 
     
Low PRC1 expression 1   
High PRC1 expression 3.108 (1.050-9.201) 0.041 
     
w/o metastasis 1   
with metastasis 3.371 (1.308-8.687) 0.01 
     
w/o recurrence not included in the variants   
with recurrence  0.211 
Table 20 Evaluation of risk factors of prognosis in 96 primary EwS patients by Cox regres-
sion analysis 
Collectively, these data suggest that PRC1 offers a therapeutic window for CIN-
induced therapy via uncoupling cytokinesis and mitosis in EwS. Its significantly 
heterogeneous overexpression in EwS correlates with poor overall survival and 
could serve as an independent prognostic factor for EwS patients. 
 
4.2 EWSR1-FLI1 directly regulates PRC1 expression 
4.2.1 EWSR1-FLI1 positively regulates PRC1 expression in a time-
dependent manner 
An established cell line model (A673/TR/shEF1) [106] that enables a doxycycline- 
(dox)-inducible shRNA-mediated knockdown of the fusion protein was used to 
test if EWSR1-FLI1 regulates PRC1 expression or not. In time-course experi-
ments silencing of EWSR1-FLI1 was accompanied by downregulation of PRC1 
(Figure 23a). These results were further validated by IHC on the protein level in 
xenografts derived from A673/TR/shEF1 in vivo, whereas no effect was observed 
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by dox-treatment of A673/TR/shCtrl xenografts expressing an inducible non-tar-
geting control shRNA (Figure 23b). 
 
Figure 23 EWSR1-FLI1 regulates PRC1 expression in a time-dependent manner 
a) Time-course knockdown of EWSR1-FLI1 in A673/TR/shEF1 EwS cells and analysis of PRC1 
and EWSR1-FLI1 expression by qRT-PCR in vitro. Dots represent means and whiskers SEM, 
n=4 biologically independent experiments. b) Analysis of PRC1 expression by IHC in xenografts 
derived from A673/TR/shEF1 and A673/TR/shCtrl cells with/without Dox-treatment for 96 h in vivo. 
Data are displayed as individual dots. Horizontal bars represent median, n≥5 biologically inde-
pendent experiments; Scale bar=200 µm. 
 
4.2.2 The enhancer activity of EWSR1-FLI1 on regulating PRC1 
expression is determined upon the length of the GGAA-motifs. 
ChIP-Seq data for EWSR1-FLI1, and epigenetic marks (H3K4me1 and H3K27ac) 
generated in EwS cell lines (A673 and SK-N-MC) [35] revealed a prominent 
EWSR1-FLI1 peak located about 90 kb apart from the PRC1 promoter. This 
EWSR1-FLI1 peak mapped to a GGAA-mSat located in an area with open chro-
matin (DNase 1 hypersensitivity site) that exhibited epigenetic characteristics for 
an active enhancer (Figure 24). Silencing of EWSR1-FLI1 was accompanied by 
a loss of EWSR1-FLI1 ChIP-Seq signals at this locus in both cell lines, and more 
interestingly, with a loss of activating H3K27ac histone marks (Figure 24). 
To verify the EWSR1-FLI1-dependent enhancer activity of this GGAA-mSat, dif-
ferent alleles from three EwS cell lines (A673, EW1 and TC71) encompassing 
variable numbers of GGAA-repeats were cloned into the pGL3 luciferase vector. 
All cloned fragments included flanking regions (in total 1,053 bp). Dual luciferase 
assays in A673/TR/shEF1 with/without silencing of EWSR1-FLI1 showed that this 
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GGAA-mSat had strong EWSR1-FLI1-dependent enhancer activity, which in-
creased with the number of consecutive GGAA-repeats (Figure 25a). Other ge-
netic variation in the cloned fragments was excluded by WGS and focal Sanger-
sequencing. Notably, the average number of GGAA-repeats at this mSat posi-
tively correlated to the PRC1 expression levels across EwS cell lines (Figure 
25b). 
 
Figure 24 Integrative genomic view (hg19) of the PRC1 locus from data of A673 and SK-N-




Figure 25 EWSR1-FLI1-bound GGAA-mSats have enhancer activity in regulation of PRC1 
expression. 
a) Luciferase reporter assays in A673/TR/shEF1 cells with/without knockdown of EWSR1-FLI1 
(Dox +/–) 72 h after transfection. Data are displayed as individual dots. Horizontal bars represent 
means and whiskers SEM, n=6 biologically independent experiments. b) PRC1 expression inten-
sity in 3 EwS cell lines as assessed by Affymetrix Clariom D microarrays (triplicates per cell line). 
The average number of GGAA-repeats at the PRC1-asscoiated GGAA-mSat is reported. One-
way ANOVA test. 
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4.2.3 Epigenomic PRC1-associated GGAA-mSat blockage via CRISPR 
interference 
To confirm the regulatory effect of this GGAA-mSat on PRC1 transcription, clus-
tered regulatory interspaced short palindromic repeats interference (CRISPRi) 
experiments in two EwS cell lines (A673, RDES) were performed. Epigenetic in-
terference with this GGAA-mSat markedly reduced PRC1 expression and prolif-
eration of derivative EwS cells (A673/TRE/dCas9/KRAB; 
RDES/TRE/dCas9/KRAB) (Figure 26). 
 
Figure 26 Epigenomic PRC1-associated GGAA-mSat blockage via CRISPR interference 
Analysis of PRC1 expression by qRT-PCR (left) and viable cells (right) in TRE-regulated dCas9-
KRAB A673 and RDES cells transduced with sgRNAs against the PRC1-associated GGAA-mSat 
and GFP sgRNAs (negative control) 15d after addition of Dox (2 µg/ml). Data are displayed as 
individual dots. Horizontal bars represent means and whiskers SEM, n=6 biologically independent 
experiments. 
 
4.2.4 CRISPR Cas9-initiaed HDR edited PRC1-mSat modification 
In order to gnomically edit the enhancer-like GGAA-mSat, a knockout (KO) ex-
periment of the PRC1-associated GGAA-mSat and a knock in (KI) experiment of 
a 24-GGAA exogenous motifs into the locus of PRC1-associated mSat via ho-
mology-directed repair (HDR) using CRISPR-Cas9 genome editing were carried 
out (Figure 27). KO of the PRC1-associated GGAA-mSat strongly reduced PRC1 
expression and proliferation of A673 cells compared to wide type cells (wt), while 
no significant differences were observed in its control cells (NC). Strikingly, re-
placement of the wt mSat comprising 14 consecutive GGAA-repeats by a ‘longer’ 
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haplotype (24 GGAA-repeats) in A673 cells significantly, increased PRC1 ex-
pression and proliferation (Figure 28). This finding has been confirmed in a sec-
ond EwS cell line RDES (Figure 29). Consistently, in a long-term colony forming 
culture, reduced sphere formation was observed accompanied with decreased 
PRC1 expression while a growing advantage was observed in KI cells (Figure 
30). 
 
Figure 27 Representative cell culture images of A673 and RDES wt cells and their CIRPSR 
Cas9-initiated HDR derivatives (magnification: 40X). 
 
 
Figure 28 CRISPR Cas9-initiaed HDR edited PRC1-mSat knock in modification 
Analysis of PRC1 expression by qRT-PCR (left) and viable cells (right) in wildtype (wt), CRISPR 
Cas9-edited negative control (NC) and CRISPR Cas9-initiated HDR edited (KO and insertion of 
24-GGAA-repeats) A673 cells 72 h after seeding. Data are displayed as individual dots. Horizon-





Figure 29 CRISPR Cas9-initiaed HDR edited PRC1-mSat knock-out modification 
Analysis of PRC1 expression (left) and proliferation (right) of RDES wt, CRISPR Cas9-initiated 
HDR edited NC and PRC1-associated GGAA-mSat KO cells 72 h after seeding. Data are dis-
played as individual dots. Horizontal bars represent means and whiskers SEM, n=6-8 biologically 
independent experiments; Two-sided Mann-Whitney test. 
 
 
Figure 30 3D-sphere formation assay of CRISPR-HDR edited EwS cells 
Sphere formation assays of A673 wt and their CRISPR/Cas9-initiated HDR edited PRC1-associ-
ated GGAA-mSat derivatives. Data are displayed as individual dots. Horizontal bars represent 
means and whiskers SEM, n=9 biologically independent experiments; Two-sided Mann-Whitney 




4.2.5 EWSR1-FLI1 physically hijacks PRC1 expression in EwS  
In order to further verify if PRC1 is a direct target gene of EWSR1-FLI1 in EwS, 
3C-PCR was performed to test whether the digested fragment containing 
EWSR1-FLI1-bound enhancer-like GGAA mSat physically forms a looping to 
PRC1 promoter region, thereby regulating PRC1 expression in EwS. In this assay, 
CRISPR Cas9-initiated HDR edited A673 EwS cells with either a genomic KO of 
PRC1-associated GGAA-mSat or an elongation of a consecutive 24-GGAA mSat 
were analyzed, individually. HindIII-digested fragment containing the PRC1-as-
sociated GGAA-mSat has been used as the bait, while the PRC1 promoter frag-
ment and three other digested fragments located in various linearize distances 
away from PRC1-associated mSat were separately tested, separately. The di-
gestion efficacy of each fragments tested in the 3C-PCR was evaluated before 
performing the assay (Figure 30). Indeed, the results confirmed a physical inter-
action of both DNA elements, which was abrogated by KO of the PRC1-associ-
ated GGAA-mSat (Figure 31). 
 
Figure 31 Digestion efficiency of HindIII fragments in 3C-PCR 
Digestion efficiency for the HindIII digested fragments analyzed in the 3C-PCR assays measured 






Figure 32 3C-PCR showing relative crosslinking frequencies 
Relative crosslinking frequencies observed in CRISPR Cas9-initiated HDR edited PRC1-associ-
ated GGAA-mSat knockout (KO) A673 EwS cells are shown in gray and insertion of 24-GGAA 
repeats in dark red. Gray shading refers to tested-fragment position and size, and black shading 
the ‘fixed’ fragment harboring the PRC1-associated GGAA-mSat. The highest crosslinking fre-
quency value in the graph was normalized and set to 1 in each replicate. Data are mean and SEM, 
n=4 biologically independent experiments. Two-sided Mann-Whitney test in all panels. 
 
In summary, high but variable expression of PRC1 in EwS is controlled by 
EWSR1-FLI1-binding to a polymorphic enhancer-like GGAA-mSat. 
 
4.3 PRC1 promotes EwS growing in vitro and in vivo 
4.3.1 Dysregulated PRC1 inhibits tumor growing triggered by CIN-
induced non-viable karyotype in vitro 
Three EwS cell lines (SK-N-MC, RDES and TC-32) transduced with two different 
Dox-inducible shRNAs against PRC1 (shCDS and shUTR) and a shCtrl were es-
tablished as described in the method part. Dox (1 µg/ml) was applied to the cul-
tured medium of transduced cells for downregulating PRC1 expression at the 




Figure 33 PRC1 knockdown efficacy test 
Left: Analysis of PRC1 mRNA levels by qRT-PCR in three EwS cell lines harboring Dox-inducible 
shPRC1 (shCDS/shUTR) or shCtrl constructs. Data are displayed as individual dots. Horizontal 
bars represent means and whiskers SEM, n=6 biologically independent experiments. Right: Rep-
resentative images of Western blots of cells depicted in (left). GAPDH served as loading control. 
 
Afterwards, Affymetrix Clariom D arrays has been performed with/without PRC1 
knockdown in SK-N-MC and RDES EwS cells. Silencing of PRC1 for 60 h, that 
is before onset of cell death to avoid obscuring events due to activation of cell 
death pathways, led to differential gene expressions. In detail, PRC1 silencing 
induced a concordant down- or upregulation of 2,896 and 381 genes, respectively, 
across shRNAs and cell lines (Figure 34). Functional gene-set enrichment 
(GSEA) followed by weighted correlation network analysis revealed that PRC1 
had pleotropic effects on diverse cellular functions linked amongst others to DNA 
packaging, chromosome formation, cell morphology, and growth (Figure 35). 
 
Figure 34 Volcano-plot of DEGs identified in transcription analysis upon PRC1 knockdown 
Volcano-plot depicting differentially expressed genes of RDES and SK-N-MC cells with/without 




Figure 35 Weighted correlation network analysis of downregulated genes in PRC1 knock-
down cells. 
In line with these predictions, Dox-induced PRC1 knockdown for 72 h strongly 
reduced the number of viable cells. while inducing massive apoptosis in all three 
cell lines in vitro (Figure 36a,b). In the long-term observation, both in 2D clono-
genic growth and 3D spheroidal growth assays PRC1 knockdown significantly 




Figure 36 PRC1 contributes to proliferation and tumorigenesis in EwS in vitro 
a) Analysis of viable cells 72 h after shRNA-mediated knockdown of PRC1. b) Analysis of apop-
tosis with/without shRNA-mediated knockdown of PRC1 for 72 h (summary of two different 
shRNAs). c) Colony-forming assays of EwS cells with Dox-inducible PRC1 knockdown or a non-
targeting shCtrl. d) Sphere formation assays of RDES, SK-N-MC, and TC32 EwS cells with Dox-
inducible knockdown of PRC1. Data are displayed as individual dots. Horizontal bars represent 
means and whiskers SEM, n=6-9 biologically independent experiments; two-sided Mann-Whitney 
test. Representative images of spheres are shown; Scare bar=50 µm. 
 
Considering PRC1’s essential function in spindle mid-zone formation [70], it is 
conceivable that these phenotypes may be explained by excessive CIN resulting 
from cytokinesis defects upon PRC1 knockdown. Indeed, PRC1 silenced EwS 
cells exhibited higher numbers of tetraploid cells through blockage of proper 
G2/M-phase transition (Figure 37a). FISH analyses using pan-centromere 
probes revealed that PRC1 knockdown for only 48 h induced likely non-viable 





Figure 37 PRC1 safeguards genome stability in EwS 
a) Analysis of cell cycle phases after knockdown of PRC1 for 72 h. Data are displayed as individ-
ual dots. Horizontal bars represent means and whiskers SEM, n=6 biologically independent ex-
periments. Two-sided Mann-Whitney test in all panels. b) Representative images of mitotic 
spreads. Each category is composed of an image of the entire mitotic spread in which DAPI (blue), 
pan-centromere (Pan-CEN)-FITC (green), and merged images are presented. Scale bar=1 µm. 
Quantification of the data are shown in pile-up bar plots depicting the percentages of aberrant 
metaphases after shRNA-mediated knockdown of PRC1 for 48 h. Horizontal bars represent 
means and whiskers SEM, n=6 biologically independent experiments. The total number of mi-
toses analyzed in each set is given at the bottom of each bar (summary of 2 different shPRC1 
constructs). Two-sided Chi-squared test. 
 
4.3.2 Silencing of PRC1 prevents tumorigenicity in vivo via generating 
CIN-induced non-viable karyotypes 
In order to see whether knockdown of PRC1 affects tumor growth of xenografted 
EwS cells in vivo, two EwS cells with a Dox-inducible shRNA against PRC1 were 
injected subcutaneously in immunocompromised NSG mice. PRC1 knockdown 
was induced when tumors were palpable (~100 mm3) via addition of Dox (2 mg/ml) 
to the drinking water. Knockdown of PRC1 reduced growth of EwS xenografts 
but not in control group (Figure 38a,b). The knockdown efficacy of PRC1 was 
proved ex vivo by IHC (Figure 38c). Silenced-PRC1 was associated with a pro-
found decreasing in proliferation indicated by Ki-67 staining and with increased 
apoptosis indicated by CC3 staining (Figure 38c). Similar to observations in vitro, 
reduced tumor growth corresponded to a higher degree of nuclear pleomorphism 
and presence of so-called ‘monster’ cells with bizarre, aneuploid, and often mul-
tilobulated nuclei, as well as to higher rates of DNA double strand breaks as indi-
cated by phospho-γH2AX stains in vivo. The human origin of ‘monster’ cells was 





Figure 38 PRC1 contributes to proliferation and tumorigenesis in EwS in vivo 
a) Tumor volume of RDES and SK-N-MC xenografts harboring either Dox-inducible shPRC1 con-
structs (shCDS/shUTR) or a non-targeting shCtrl. When tumors were palpable, mice were ran-
domized and treated with either vehicle (–) or Dox (+). Data are mean and SEM, n≥5 animals per 
condition. P-values were calculated at the experimental endpoint; two-sided Mann-Whitney test. 
b) Tumor weight (g) of xenografts from SK-N-MC and RDES cells containing two Dox-inducible 
shPRC1 constructs (shCDS/shUTR) or a non-targeting shCtrl. Data are displayed as individual 
dots. Horizontal bars represent means and whiskers SEM, n≥5 animals per condition. c) Repre-
sentative micrographs of xenografts stained by IHC for PRC1 (IRS), Ki-67 and cleaved caspase-
3 (CC3), as well as corresponding quantifications of indicated parameters. Data are displayed as 
individual dots. Horizontal bars represent median IRS of PRC1 or means and whiskers SEM for 
positivity, respectively; n≥5 animals per condition; two-sided Mann-Whitney test; Scale bar=100 
µm. d) Representative micrographs of xenografts stained with H&E and human mitochondria (mt), 
and quantification of ‘monster’ cells per low-power field (LPF) at 20× magnification. Data are dis-
played as individual dots. Horizontal bars represent means and whiskers SEM, n≥5 animals per 
condition; two-sided Mann-Whitney test; Scale bar=20 µm. e) Representative micrographs of xen-
ografts stained by IHC for phospho-γH2AX, and its quantification per HPF. Data are displayed as 
individual dots. Horizontal bars represent means and whiskers SEM, n≥5 animals per condition; 
Two-sided Mann-Whitney test; Scale bar=100 µm.  
 
In synopsis, the results suggested that PRC1 is critical for proper cell division in 
EwS, and that disruption of the delicate balance between mitosis and cytokinesis 
causes non-viable karyotypes in this otherwise genetically silent pediatric cancer. 
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4.4 Therapeutically targeting PRC1 via PLK1 inhibition in EwS 
4.4.1 PRC1 expression confers sensitivity towards PLK1 inhibition in 
vitro 
Since there are no direct inhibitors of PRC1 available to date, its major interacting 
partner PLK1 could serve as a surrogate target. PRC1 is a direct substrate of 
PLK1. PLK1 phosphorylates and binds to PRC1, which enables the formation of 
the PLK1:PRC1 complex critical for PLK1 translocation to the central spindle to 
initiate cytokinesis [68], [69]. Indeed, both genes were highly and significantly co-
expressed in primary EwS tumors (n=196, rPearson=0.58, P=2.2-16) indicated 
by Pearson correlation analysis (Figure 39a). Thus, EwS models were treated 
with two small molecule ATP-competitive PLK1 inhibitors (BI2536, BI6727 [alias 
Volasertib]) being in clinical trials (Appendix B). Both inhibitors showed strong 
anti-proliferative effects on RDES and TC32 EwS cells at the lower nanomolar 
range (BI2536 ~5 nM, BI6727 ~20 nM) (Figure 39b,c). Even more strikingly, di-
rect and indirect downregulation of PRC1 either by RNA interference or genetic 
KO of the PRC1-associated GGAA-mSat dramatically diminished the sensitivity 
of EwS cells toward both PLK1 inhibitors (Figure 39c). In contrast, upregulation 
of PRC1 via CRISPR-mediated elongation of the PRC1-associated GGAA-mSat 
significantly increased their sensitivity toward both inhibitors (Figure 39c). To test 
the long-term effects of these inhibitors, 2D clonogenic and 3D sphere formation 
assays on RDES wt and TC32 wt cells applying the pre-determined median ef-
fective dose (ED50) of each respective inhibitor (BI2536 ~5 nM, BI6727 ~20 nM) 
was carried out. Both inhibitors strongly reduced clonogenic and spheroidal 
growth of RDES and TC32 EwS cells as compared to DMSO controls while in-
ducing massive apoptosis (Figure 38d-f). In sum, these findings indicated that 
EwS cells with high PRC1 expression are very sensitive to PLK1 inhibition, and 




Figure 39 PRC1 primers EwS to PLK1 inhibition in vitro 
a) Pearson correlation analysis of PLK1 and PRC1 mRNA expression levels in 196 primary EwS 
tumors. b) Heatmaps depicting the average percentage of growth inhibition in RDES and TC32 
EwS cells containing either Dox-inducible specific shPRC1 (shCDS/shUTR) or non-targeting 
shCtrl constructs with/without Dox-treatment and after 72 h of PLK1 inhibition; n=6 biologically 
independent experiments. c) Inhibitory concentrations of 50% viability (IC50) in CRISPR Cas9-
edited A673 EwS cells after 72 h of PLK1 inhibition. d) Colony-forming assays of RDES and TC32 
cells treated with PLK1 inhibitor BI2536 or BI6727. e) Sphere formation assays of RDES and 
TC32 EwS cells treated with BI2536 or BI6727. Representative images of spheres are shown; 
Scale bar=50 µm. f) Analysis of apoptosis of RDES and TC32 EwS cells with/without PLK1 inhi-
bition at indicated dose for 72 h using Annexin V/PI staining. For panel c-f, data are displayed as 
individual dots. Horizontal bars represent means and whiskers SEM, n=6-9 biologically independ-
ent experiments. Two-sided Mann-Whitney test. 
4.4.2 PRC1 expression confers sensitivity towards PLK1 inhibition in 
vivo 
To confirm the PRC1-dependency of PLK1 inhibition in vivo, CRISPR Cas9-initi-
ated HDR edited A673 EwS cells were xenografted in NSG mice. Once tumors 
were palpable, mice were treated with BI2536 or BI6727 once per week via tail 
veil injection at clinically achievable dosages (Figure 40a). Treatment of mice 
xenografted with highly PRC1 expressing EwS cells led to strong inhibition of 
tumor growth and even tumor regression with massive genomic chaos after only 
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three cycles of treatment (Figure 40b,c) without overt adverse effects, such as 
weight loss (Figure 40d). Tumor regression was accompanied by induction of 
apoptosis and cell death as evidenced by significantly increased numbers of cells 
positive for CC3 and Ki67, respectively (Figure 40e). Such anti-tumor effects 
might be induced by generations of massive genomic chaos after PLK1 inhibition 
as indicated by a higher positivity of phosphor-γH2AX and significantly increased 
mitotic failure (Figure 40d,e). Remarkably, mice with total tumor regression did 
not show any sign of tumor recurrence up to 25 days after the last cycle as con-
firmed by necropsy and IHC (Figure 40f,g). In contrast, xenografts from A673 
EwS cells with KO of the PRC1-associated GGAA-mSat exhibited delayed tumor 
growth and only progressive disease during treatment despite a 4th injection was 
administered (Figure 40b-d). Together, these findings suggested that genomi-
cally silent pediatric cancers, such as EwS, may be very sensitive to PLK1 inhi-
bition in case of high PRC1 expression. In support of this notion, analysis of 
matched in vivo gene expression and drug-response data from pediatric tumor 
types (including EwS) [107] with relatively silent genomes revealed that good re-
sponses to BI6727 (Volasertib) were observed exclusively among PRC1 high ex-
pressing xenografts (defined by median expression; P=0.0325, Fisher’s exact 




Figure 40 PRC1 primers EwS to PLK1 inhibition in vivo 
a) Schematic of the experimental setting of PLK1 inhibitor treatment (BI2536, BI6727) in vivo. 
NSG mice were xenografted with A673 CRISPR Cas9-edited negative control (NC) cells and 
A673 CRISPR HDR-edited PRC1-associated GGAA-mSat KO cells. When tumors were palpable, 
mice were randomized and treated with either vehicle or PLK1 inhibitor BI2536 in a dose of 40 
mg/kg or BI6727 in a dose of 30 mg/kg. b) For each condition, the tumor volume of ≥6 mice were 
plotted over the time of treatment as an individual line. Representative micrographs of H&E and 
PRC1 staining, positivity of CC3 as well as phospho-gH2AX per HPF. Scale bar=100 µm. c) 
Quantification of IRS of PRC1 and positivity of phospho-gH2AX and cleaved caspase-3 (CC3) per 
HPF of xenografts related to b). Data are displayed as individual dots. Horizontal bars represent 
median IRS of PRC1 or means and whiskers SEM for positivity, respectively; n≥6 animals per 
condition; Two-sided Mann-Whitney test. d) Body weight of mice during intravenous PLK1 inhib-
itor treatment with BI2536 or BI6727. Dots represent means and whiskers SEM, n≥6 biologically 
independent animals per condition. e) Representative micrographs of xenografts stained with 
H&E related to b). Quantification of the data are shown in pile-up bar plots depicting the percent-
age of mitotic defects in each condition (at least 30 mitoses per tumor were evaluated). Horizontal 
bars represent means and whiskers SEM, n=3–7 animals per condition; Two-sided Chi-squared 
test; Scale bar=10 µm. f) Tumor volume of A673 CRISPR Cas9-edited NC xenografts showing 
complete tumor regression during PLK1 inhibitor treatment and 25 d additional observation. g) 
Upper: Images of necropsy on A673 CRISPR Cas9-edited NC xenografts showing complete tu-
mor regression after 3 cycles of PLK1 inhibitor treatment with BI2536 or BI6727 followed by 25 d 
additional observation. Lower: Immunohistological assessment of the injection site of the tumor 













KT-14 Extracranial rhabdoid tumor 19.9114 11.5808 13.9151 PD1 Poor 
KT-12 Atypical teratoid/rhabdoid tumor (ATRT) 27.4067 22.8022 18.2974 PD2 Poor 
CHLA-
79 Neuroblastoma 34.1437 21.5677 11.8097 PD1 Poor 
KT-11 Wilms tumor 37.5781 29.6465 28.0239 PD2 Poor 
TC-71 Ewing sarcoma 38.8586 27.779 14.1324 PD1 Poor 
BT-29 Atypical teratoid/rhabdoid tumor (ATRT) 44.6578 29.15 18.2936 PD1 Poor 
CHLA-
258 Ewing sarcoma 55.245 51.1741 21.9456 PD1 Poor 
KT-13 Wilms tumor 57.4319 48.3395 43.664 PD2 Poor 
SK-
NEP-1 Ewing sarcoma 62.8287 40.7332 25.9604 PD2 Poor 
NB-
1771 Neuroblastoma 64.346 25.5629 36.6809 PD2 Poor 
NB-




coma 70.6508 33.9127 53.0211 CR Good 
NB-
1643 Neuroblastoma 73.4423 33.4227 33.8688 SD Good 
Rh-10 Alveolar rhabdomyosar-coma 75.3155 44.0557 51.2629 PD1 Poor 
KT-10 Wilms tumor 78.1368 31.3835 63.3262 PD1 Poor 
EW-5 Ewing sarcoma 78.5027 69.6248 41.0436 PD1 Poor 
Rh-30 Alveolar rhabdomyosar-coma 79.1408 32.4619 59.4743 PD2 Poor 
NB-
1691 Neuroblastoma 94.2106 51.5524 45.3638 CR Good 
NB-SD Neuroblastoma 118.62 38.0142 50.511 CR Good 
       
  
P value (good versus poor 
response) 0.0325 0.3034 0.3034     
Table 21 Analysis of matched in vivo gene expression and drug-response data from pedi-
atric tumor types with relatively silent genomes [109] 
 
 
4.4.3 PLK1 inhibitors synergize with chemotherapeutic drugs in a PRC1-
dependent manner 
In the clinical setting, Vincristine (VCR) and Doxorubicin (Doxo) are highly active 
chemotherapeutics employed in first-line treatment and relapsed EwS [33]. 
Hence, the potential synergistic effects of PLK1 inhibition with both drugs were 
studied in this thesis. As shown in Figure 41a, the microtubule-destabilizing drug 
VCR showed highly synergistic effects (positive Bliss score) at nanomolar con-
centrations in RDES cells, which was strongly diminished upon PRC1 knockdown. 
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This PRC1-dependent effect was confirmed in TC32 EwS cells (Figure 41b), and 
corresponded to prior observations of synergy of BI6727 with VCR in this cell line 
[108]. This combination therapy also significantly reduced the necessary IC50 of 
PLK1 inhibitors (Figure 41c), which may help to mitigate their potential adverse 
effects. However, such synergistic effect was not observed for the intercalating 
drug Doxo across both cell lines and PLK1 inhibitors regardless of the PRC1 lev-
els (Figure 42a). Yet, it is noteworthy that both PLK1 inhibitors were still effective 
at nanomolar concentrations in EwS cell lines being highly resistant toward Doxo 
(Figure 42b), and that they could partially restore their Doxo-sensitivity (Figure 
41d,e). 
 
Figure 41 PLK1 inhibitors show synergistic effects when combined with chemo agents in 
EwS 
a-b) Excess over Bliss analysis of RDES a) and TC32 cells b) with/without PRC1 knockdown 
treated with combinations of Vincristine (VCR) and the PLK1 inhibitors BI2536 or BI6727 (red 
color indicates synergy). Summary level (mean) data from n=6 biologically independent experi-
ments are shown. c) Dose reduction index (DRI) of PLK1 inhibitor BI2536 or BI6727 at IC50 level 
when combined with VCR in RDES and TC32 EwS cells. d) Dose-response curves of two Doxo-
rubicin (Doxo)-resistant EwS cell lines A673 and TC71 treated with Doxo combined with PLK1 
inhibitor BI2536 or BI6727 for 72 h. The reverse index (RI) is given. e) Median effective dose 
(ED50) for Doxo-treatment alone or in combination with PLK1 inhibitor BI2536 or BI6727 for 72 h 
in Doxo-resistant A673 and TC71 cells. Data are displayed as individual dots. Horizontal bars 
represent means and whiskers SEM, n=6 biologically independent experiments. Two-sided 




Figure 42 Combination test of PLK1 inhibitors with Doxorubicin in EwS cells 
a) Excess over Bliss analysis of RDES and TC32 EwS cells with/without PRC1 knockdown treated 
with combinations of Doxorubicin and the PLK1 inhibitors BI2536 or BI6727 (red color indicates 
synergy). Summary level data (means) from n=6 biologically independent experiments are shown. 
b) Dose response of two Doxorubicin-resistant (Doxo-res) EwS cell lines (A673, TC71) treated 
with the PLK1 inhibitors BI2536 or BI6727. Concentration of either PLK1 inhibitor below inhibitory 
concentrations of 90% viability (IC10) was defined as non-toxic (dashed lines). Dots represent 
means and whiskers SEM, n=6 biologically independent experiments. 
In summary, these data indicated that PRC1-dependent PLK1 inhibitor treatment 
acts synergistically with other drugs employed in routine EwS therapy, and even 
is also effective against chemo-resistant EwS cells. 
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5. Discussion  
CIN and cancer have been initially linked together by Theodor Boveri [109]. Alt-
hough it is still unclear now how CIN-directed therapy seems to be a promising 
and novel cancer intervention [110]. Mitosis or cytokinesis defects can lead to 
CIN and chromosome mis-segregation [36]. EwS is genetically remarkably stable, 
containing a nearly diploid genome, with a single recurrent driver mutation 
EWSR1-FLI1 [33]. Although fruitful research findings were achieved in the bio-
logical field, exploitation of CIN-directed therapies still at its early stage in clinical. 
Thus, this thesis anticipates that properly exploiting CIN-induced treatment has 
great potential to affect clinical outcomes, especially in cancers with largely silent 
genomes, such as EwS. 
The thesis aims at provoking cytokinesis failure by targeting PRC1 in EwS. The 
data represented in this thesis showed that PRC1 is heterogeneously overex-
pressed in EwS at both mRNA and protein level and its overexpression correlates 
with poor overall survival, and could additionally serve as an independent prog-
nostic factor for EwS patients. More importantly, PRC1 is the most overexpressed 
gene in EwS, which offers a large therapeutic window for a CIN-directed therapy. 
These findings indicate that the therapeutical potential of specifically targeting 
PRC1 in highly proliferating EwS cells is less toxic for normal tissues.  
The data in this thesis demonstrated that the observed heterogenous PRC1 ex-
pression in EwS tumors may result from a direct regulation of EWSR1-FLI1, the 
major fusion oncoprotein in EwS. A distal PRC1-associated GGAA mSat bound 
by EWSR1-FLI1 showed strong length- and EWSR-FLI1-dependent enhancer 
activity in EwS cell lines. Moreover, epigenetically silencing or removing this 
GGAA-mSat significantly reduced PRC1 expression and proliferation, while an 
epigenetic elongation of 24-GGAA motifs replaced by a natural 14-consequtive 
GGAA repeats significantly increased PRC1 expression and cell viability. A 
PRC1-associated GGAA-mSat physically interacts with the promoter of PRC1 
through spatially forming a loop in the genome as shown in the 3C-PCR assay. 
The cooperation of a dominant cell cycle regulator (here PRC1) with polymorphic 
regulator elements (here GGAA-mSats), that are hitherto frequently considered 
as mere junk DNA, safeguards EwS genome stability required for disease-pro-
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motion and explains the inter-individual diversity in clinical outcomes. This ge-
netic mechanism shows how oncogenic hijacking of a cytokinesis regulator in 
cancer provides a rationale for novel targeted therapies. 
 GSEA followed by weighted correlation network analysis examined >285,000 
transcripts and isoforms, revealing that PRC1 had pleotropic effects on diverse 
cellular functions linked amongst others to DNA packaging, chromosome for-
mation, cell morphology, and growth. Functional in vitro and in vivo experiments 
consistently showed a decreased proliferation followed by an increased apopto-
sis in the context of downregulated PRC1 expression, suggesting an anti-tumor 
effect of PRC1 in EwS. The anti-tumor effects could be explained by excessive 
CIN resulting from cytokinesis defects upon PRC1 knockdown. Indeed, there is 
an G2/M cell cycle arrest in PRC1-knockdown cells in EwS. These dividing tetra-
ploid cells are susceptible to develop aneuploid cells because of, e.g., the extra 
number of centrosomes resulting in chromosome mis-segregation during mitosis 
[80], [111], [112]. FISH analyses using pan-centromere probes revealed that 
PRC1 knockdown profoundly induced a greater amount of various mitotic defects 
and non-viable karyotypes compared to controls. Correspondingly, IHC staining 
revealed a higher degree of nuclear pleomorphism and the presence of so-called 
‘monster’ cells with bizarre, aneuploid, and often multilobulated nuclei, as well as 
higher rates of DNA double strand breaks as indicated by phospho-gammaH2AX 
stains in vivo, which is supported by the finding of a new connection between 
cytokinesis and DNA damage [113].  
An evolving interest in the polo-like kinase (PLK) family as an attractive therapeu-
tic target in oncology has attracted massive attention for the last few decades. 
PLK1 is deemed extremely important because of its central role in mitosis and 
cytokinesis [114]. Notably, many cancers, including pediatric tumors, often over-
express PLK1 [115]. This interested is further warranted by the improved safety 
profile of PLK1 inhibitors versus classical mitotic drugs [116]. However, the re-
sponses to PLK1 inhibitors from different studies were discrepant, suggesting 
PLK1 inhibition (PLK1i) may not be propitious to all cancers [116], [117]. There-
fore, highlighting predictive markers for vulnerability of cancer cells towards PLK1 
inhibitors is of great interest to affect and/or foretell drug efficacy, which will finally 
be used to optimize therapy options for patients.  
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PRC1 interacts with PLK1 to directly recruit regulator proteins to the spindle mi-
dzone [61], [118]. Indeed, the results in this thesis showed a strong anti-prolifer-
ative effect of PLK1 inhibitor treatment on EwS cells at a relatively low dose, 
which was critically dependent on the intensity of PRC1 expression. Interestingly, 
such sensitivity of PLK1i to EwS cells did not depend on the TP53 status, which 
was previously confirmed in other cancer entities [119], [120]. Thus, EwS patients 
with mutant TP53, who normally present with more aggressive disease, could 
also benefit from PLK1 inhibitor treatment. Considering that PLK1i alone may be 
inefficient to completely cure patients, combining a PLK1 inhibitor with other 
chemo-agents could be necessary. It has been reported that some PLK1 inhibi-
tors showed synergistic effects with microtubule-destabilizing agents such as 
VCR, in pediatric rhabdomyosarcomas and neuroblastoma cells [115], [121]. 
VCR is currently used as the standard 1st line combination chemotherapy for pri-
mary and relapsed EwS [122]. Similar to a previous paper showing the synergistic 
effect of a PLK1 inhibitor (BI6727) with VCR in EwS cells [108], the results in this 
thesis illustrated that PLK1 inhibitors (BI2536 and BI6727) when combined with 
VCR showed synergistic lethality via  triggering massive cell apoptosis in EwS 
cells. It has been reported that the synergistic lethality could induce mitotic block-
age followed by mitochondrial apoptosis through breaking down anti-apoptotic 
BCL2 proteins and caspase dependent/independent pathways [123]. Interest-
ingly, PRC1 expression to a large extend determines the vulnerability of EwS 
cells towards PLK1i/VCR cotreatment, which might be explained by the fact that 
PLK1i/VCR induced mitotic arrest is required for apoptosis since preventing cells 
from entering mitosis significantly reduced PLK1i/VCR induced apoptosis [123]. 
Additionally, PLK1 inhibitors have been reported being able to overcome doxoru-
bicin resistance in osteosarcoma [120]. In this thesis, the application of a PLK1 
inhibitor was able to at least partially revert the resistance and restore the sensi-
tivity of EwS cells toward doxorubicin, which might be mediated by inducing dox-
orubicin nuclear accumulation [120]. 
Collectively, the results in this thesis demonstrate that the EWSR1-FLI1-medi-
ated high PRC1 expression sensitizes EwS cells towards PLK1i, and renders 
PRC1 as a promising predictive biomarker for therapies evoking cytokinesis de-
fects and mitotic catastrophe (Figure. 43). CIN-directed therapies in cancers with 
largely silent genomes, such as EwS, seem to be a promising cancer intervention. 
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Still, careful biomarker-guided selection of patients is required to identify those 
patients who may benefit in particular from therapeutic modulation of CIN. In this 
regard, PLK4 inhibition was recently recognized as a therapeutic treatment option 
specifically for TRIM37-amplified neuroblastoma and breast cancer by causing 
centromere-dysfunction [124], [125]. Notably, the findings in this thesis also ex-
plain why previous preclinical testing of PLK1i in non-preselected EwS models 
may have yielded controversial results on its efficacy [107]. It is conceivable that 
the PRC1-related mechanism identified in EwS model may be translatable to 
other cancers for which immunohistochemical detection of high PRC1 levels 
could serve as a broadly available and inexpensive predictive biomarker. 
 
Figure 43 Schematic illustrating key findings of this study 
EWSR1-FLI1-mediated high PRC1 expression through binding to a proximal enhancer-like 
GGAA-mSat in EwS promotes poor clinical outcomes while simultaneously creates a therapeutic 
vulnerability toward pharmacological PLK1 inhibition by triggering mitotic catastrophe. 
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6. Limitations and future perspective 
In this thesis, the data demonstrates that EWSR1-FLI1-steered high PRC1 ex-
pression sensitizes EwS cells towards a PLK1 inhibitor, one broadly tested kinase 
inhibitor ripe for therapeutic exploitation yet with divergent responses. The results 
in this thesis indicate to render PRC1 as a promising predictive biomarker for 
therapies evoking cytokinesis defects and mitotic catastrophe, particularly in can-
cers with relatively ‚silent‘ genomes. However, to further solidify the PRC1-related 
mechanism of PLK1i and to successfully translate this pre-clinical finding to clin-
ical application, there are several gaps needed to be fulfilled:  
a) The prognostic value of PRC1 in EwS was consistently identified in two large 
retrospective cohorts in this thesis. A third perspective evaluation in another large 
cohort of EwS patients would be desirable for this quite rare disease.  
b) Our work lacks the data from EwS patient-derived xenograft model (PDX) or 
EwS patients who received PLK1 inhibitor treatment in a clinical context. In this 
regard, the responses to PLK1 inhibition from real EwS tumors/patients can be 
collected to verify the value of PRC1 stratification for predicting PLK1 inhibitor 
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Appendix A: GSEA results upon PRC1 knockdown 
Pathway P-value (adjusted) NES 
GO_MATURATION_OF_5_8S_RRNA 0.008806614 2.3038047 
GO_SPLICEOSOMAL_TRI_SNRNP_COMPLEX 0.009372064 2.30114 
GO_MATURATION_OF_SSU_RRNA 0.00985258 2.1500123 
GO_REGULATION_OF_PROTEIN_POLYUBIQUITINA-
TION 0.008061762 2.09080316 
GO_APICAL_PART_OF_CELL 0.005259368 -1.7513334 
GO_SENSORY_ORGAN_MORPHOGENESIS 0.006701649 -1.7520153 
GO_CALMODULIN_BINDING 0.006701649 -1.7541509 
GO_BONE_DEVELOPMENT 0.005259368 -1.7572234 
GO_CELL_DIVISION 0.005259368 -1.7647592 
GO_CALCIUM_ION_TRANSMEM-
BRANE_TRANSPORT 0.005259368 -1.7682016 
GO_MICROTUBULE_BINDING 0.005259368 -1.7732232 
GO_EPITHELIAL_CELL_DEVELOPMENT 0.006701649 -1.7955944 
GO_AXON_DEVELOPMENT 0.005259368 -1.7989699 
GO_MICROTUBULE_ASSOCIATED_COMPLEX 0.006701649 -1.8025688 
GO_MICROTUBULE_CYTOSKELETON_ORGANIZA-
TION 0.005259368 -1.8039794 
GO_SPINDLE_POLE 0.005259368 -1.8063112 
GO_EXTRACELLULAR_STRUCTURE_ORGANIZA-
TION 0.005259368 -1.8067486 
GO_FOREBRAIN_DEVELOPMENT 0.005259368 -1.8085248 
GO_CELL_SUBSTRATE_ADHESION 0.005259368 -1.8180133 
GO_REGULATION_OF_NERVOUS_SYSTEM_DEVEL-
OPMENT 0.005259368 -1.8216658 
GO_FAT_CELL_DIFFERENTIATION 0.005259368 -1.8316975 
GO_EXTRACELLULAR_MATRIX 0.005259368 -1.8576189 
GO_GROWTH_FACTOR_BINDING 0.008913796 -1.8594985 
GO_CHONDROCYTE_DIFFERENTIATION 0.008913796 -1.8618331 
GO_MITOTIC_NUCLEAR_DIVISION 0.005259368 -1.871198 
GO_CONDENSED_CHROMOSOME_CENTRO-
MERIC_REGION 0.005259368 -1.8764235 
GO_CALCIUM_ION_TRANSMEMBRANE_TRANS-
PORTER_ACTIVITY 0.006989604 -1.8952211 
GO_POLYOL_METABOLIC_PROCESS 0.009200077 -1.9068411 
GO_MAINTENANCE_OF_LOCATION 0.005259368 -1.9291997 
GO_BASOLATERAL_PLASMA_MEMBRANE 0.005259368 -1.9566709 
GO_CEREBRAL_CORTEX_DEVELOPMENT 0.005259368 -1.9839783 
GO_NEURON_MIGRATION 0.005259368 -1.9887176 
GO_NEGATIVE_REGULATION_OF_GENE_EXPRES-
SION_EPIGENETIC 0.005259368 -2.0290812 
GO_GLIAL_CELL_ACTIVATION 0.005872163 -2.0572492 
GO_NEGATIVE_REGULATION_OF_CHROMATIN_OR-
GANIZATION 0.005353443 -2.0599932 
GO_NEGATIVE_REGULATION_OF_GENE_SILENC-
ING 0.005725357 -2.1035647 
GO_PROTEIN_DNA_COMPLEX 0.005259368 -2.1512822 
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GO_NUCLEOSOME_ORGANIZATION 0.005259368 -2.2260644 
GO_CHROMATIN_ASSEMBLY 0.005259368 -2.3250757 
GO_DNA_PACKAGING_COMPLEX 0.005259368 -2.4905418 
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Appendix B: Summary of clinical trials for PLK1 inhibitor BI2536 and BI6727 
Drug Study title NCT number 
BI2536 
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, 
Unresectable Pancreatic Cancer NCT00710710 
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clini-
cal Benefit NCT02211859 
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer NCT02211833 
BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit NCT02211872 
Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pan-
creatic Cancer NCT02215044 
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia NCT00701766 
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non-Small Cell Lung Cancer NCT00376623 
BI 2536 Second Line Monotherapy in SCLC NCT00412880 
Phase II Study of BI 2536 in Prostate Cancer NCT00706498 
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive 
Non-Hodgkin's Lymphoma (NHL) NCT00243087 
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors NCT00526149 
BI6727 
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) NCT01662505 
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours NCT01145885 
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours NCT01348347 
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumor NCT00969761 
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) NCT02003573 
A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia NCT02527174 
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours NCT02273388 
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Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia NCT02905994 
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia NCT02861040 
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less 
Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed NCT02722135 
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours NCT01772563 
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in 
Patients With Advanced Solid Tumours NCT01206816 
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers NCT00969553 
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors NCT01022853 
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leuke-
mia NCT02201329 
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas NCT02875002 
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in 
Advanced NSCLC NCT00824408 
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL NCT02757248 
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes NCT02721875 
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome 
(MDS) and Acute Myeloid Leukemia (AML) NCT02198482 
BI 6727 (Volasertib) Randomized Trial in Ovarian Cancer NCT01121406 
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML NCT01957644 
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer NCT01023958 
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Pediatric Patients With Advanced Cancers for Whom no 
Therapy is Known NCT01971476 
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia NCT00804856 
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid 
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